0001493152-17-005105.txt : 20170512 0001493152-17-005105.hdr.sgml : 20170512 20170512123029 ACCESSION NUMBER: 0001493152-17-005105 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170512 DATE AS OF CHANGE: 20170512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immune Therapeutics, Inc. CENTRAL INDEX KEY: 0001559356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593226705 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54933 FILM NUMBER: 17837426 BUSINESS ADDRESS: STREET 1: 37 NORTH ORANGE AVENUE STREET 2: SUITE 607 CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: (888) 613-8802 MAIL ADDRESS: STREET 1: 37 NORTH ORANGE AVENUE STREET 2: SUITE 607 CITY: ORLANDO STATE: FL ZIP: 32801 FORMER COMPANY: FORMER CONFORMED NAME: TNI BIOTECH, INC. DATE OF NAME CHANGE: 20121001 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

[ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from ___________ to ____________

Commission File Number __________________

IMMUNE THERAPEUTICS, INC.

(Exact name of small business issuer as specified in its charter)

Florida

59-3226705

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

37 North Orange Ave, Suite 607, Orlando, FL 32801

(Address of principal executive offices)

888-613-8802

(Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]		Accelerated Filer [ ]

Non-Accelerated Filer [ ]		Smaller Reporting Company [X]

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes [ ] No [X]

As of May 12, 2017 there were 304,140,678 shares of Common Stock outstanding.

TABLE OF CONTENTS

	PART I – FINANCIAL STATEMENTS
Item 1.	Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Conditions and Results of Operations	26

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32

Item 4.	Controls and Procedures	32

	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	33

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33

Item 3.	Default upon Senior Securities	34

Item 4.	Mine Safety Disclosures

Item 5.	Other Information

Item 6.	Exhibits	35

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained or incorporated by reference in this Quarterly Report on Form 10-Q are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions and projections. Forward-looking statements are included, for example, in the discussions about:

	●	strategy;
	●	new product discovery and development;
	●	current or pending clinical trials;
	●	our products’ ability to demonstrate efficacy or an acceptable safety profile;
	●	actions by the FDA and other regulatory authorities;
	●	product manufacturing, including our arrangements with third-party suppliers;
	●	product introduction and sales;
	●	royalties and contract revenues;
	●	expenses and net income;
	●	credit and foreign exchange risk management;
	●	liquidity;
	●	asset and liability risk management;
	●	the outcome of litigation and other proceedings;
	●	intellectual property rights and protection;
	●	economic factors;
	●	competition; and
	●	legal risks.

Any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “plans,” “may,” “could,” “will,” “will continue,” “seeks,” “should,” “predict,” “potential,” “outlook,” “guidance,” “target,” “forecast,” “probable,” “possible” or the negative of such terms and similar expressions. Forward-looking statements are subject to change and may be affected by risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as required by law, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws.

We caution you that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, under “Risk Factors” and elsewhere in this Annual Report and in our other public reports filed with the Securities and Exchange Commission. It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements. We can offer no assurance that our estimates or expectations will prove accurate or that we will be able to achieve our strategic and operational goals.

Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

	●	our lack of operating history;
	●	our current and future capital requirements and our ability to satisfy our capital needs;
	●	our inability to keep up with industry competition;
	●	interpretations of current laws and the passages of future laws;

	●	acceptance of our business model by investors and our ability to raise capital;
	●	our drug discovery and development activities may not result in products that are approved by the applicable regulatory authorities. Even if our drug candidates do obtain regulatory approval they may never achieve market acceptance or commercial success;
	●	our reliance on key personnel, including our ability to attract and retain scientists;
	●	our reliance on third party manufacturing to supply drugs for clinical trials and sales;
	●	our limited distribution organization with no sales and marketing staff;
	●	our being subject to product liability claims;
	●	our reliance on key personnel, including our ability to attract and retain scientists;
	●	legislation or regulation that may increase the cost of our business or limit our service and product offerings;
	●	risks related to our intellectual property, including our ability to adequately protect intellectual property rights;
	●	risks related to government regulation, including our ability to obtain approvals for the commercialization of some or all of our drug candidates, and ongoing regulatory obligations and continued regulatory review which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements; and
	●	our ability to obtain regulatory approvals in foreign jurisdictions to allow us to market our products internationally.

Moreover, new risks regularly emerge and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this prospectus are based on information available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Annual Report.

JUMPSTART OUR BUSINESS STARTUPS ACT

We qualify as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, the last day of our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

As an emerging growth company, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

	●	being permitted to present only two years of audited financial statements and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this annual report;
	●	not being requested to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);
	●	reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
	●	exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We will remain an emerging growth company until the earliest to occur of: (i) our reporting $1 billion or more in annual gross revenues; (ii) the end of fiscal year 2019; (iii) our issuance, in a three year period, of more than $1 billion in non-convertible debt; and (iv) the end of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million on the last business day of our second fiscal quarter.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31, 2017			December 31, 2016
ASSETS

Current Assets:
Cash and cash equivalents	$	98,113		$	74,389
Total current assets		98,113			74,389

Fixed Assets:
Computer equipment, net of accumulated depreciation of $8,032 and $7,888 respectively		1,706			1,850
Deposits		200			200

Total assets	$	100,019		$	76,439

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:
Accounts payable	$	1,666,406		$	1,818,605
Accrued liabilities		3,980,417			3,156,759
Current portion of notes payable, net of debt discount		4,742,259			4,225,419

Total current liabilities		10,389,082			9,200,783

Total liabilities		10,389,082			9,200,783

Commitments and Contingencies (Note 10)

Stockholders’ Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 275,640,678 and 250,428,133 shares issued and outstanding respectively		27,564			25,043
Additional paid in capital		361,542,431			360,420,026
Stock issuances due		1,432,883			962,429
Prepaid services		(876,666	)		(822,500	)
Accumulated deficit		(368,288,346	)		(365,718,976	)

Deficit attributable to common stockholders		(6,162,134	)		(5,133,978	)
Non-controlling interest		(4,126,929	)		(3,990,366	)
Total stockholders’ deficit		(10,289,063	)		(9,124,344	)
Total liabilities and stockholders’ deficit	$	100,019		$	76,439

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months ended
	March 31, 2017			March 31, 2016
Revenues, net	$	-		$	3,463

Operating expenses:
Selling, general and administrative		666,091			939,341
Research and development expense		118,656			(18,842	)
Stock issued for services G&A		731,288			1,983,837
Warrant valuation expense		-			2,078,199
Depreciation and amortization expense		144			547
Total operating expenses		1,516,179			4,983,082

Loss from operations		(1,516,179	)		(4,979,619	)

Other income (expense):
Interest expense		(575,828	)		(301,444	)
Loss on settlement of debt		(613,926	)		(1,364,339
Total other income (expense)		(1,189,754	)		(1,665,783	)
Net loss	$	(2,705,933	)	$	(6,645,402	)
Net loss attributable to non-controlling interest		(136,563	)		(44,120	)
Net loss attributable to common shareholders		(2,569,370	)		(6,601,282	)
Basic loss per share to common shareholders	$	(0.01	)	$	(0.03	)
Weighted average number of shares outstanding		259,291,541			190,923,381

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD ENDED MARCH 31, 2017

(Unaudited)

	Common Stock				Additional Paid-in			Stock To		Prepaid			Accumulated			Non-Controlling
	Shares		Amount		Capital			Be Issued		Services			Deficit			Interest			Total

Balance December 31, 2016		250,428,133	$	25,043	$	360,420,026		$	962,429	$	(822,500	)	$	(365,718,976	)	$	(3,990,366	)	$	(9,124,344	)

Issuance of common stock for prepaid services		6,045,460		605		314,396			470,454		(420,000	)		-			-			365,455

Amortization of prepaid services		-		-		-			-		365,834			-			-			365,834

Issuance of common stock in exchange for debt		17,510,638		1,751		808,174					-			-			-			809,925

Issuance of common stock for exercise of warrants		1,656,447		165		(165	)				-			-			-			-

Net loss		-		-		-			-		-			(2,569,370	)		(136,563	)		(2,705,933	)

Balance as of March 31, 2017		275,640,678		27,564		361,542,431			1,432,883		(876,666	)		(368,288,346	)		(4,126,929	)		(10,289,063	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2017			March 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(2,705,933	)	$	(6,645,402	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation		144			547
Amortization of debt discount		35,346			-
Amortization of stock issued for prepaid services		365,834			669,667
Stock issued for services		365,455			1,314,169
Stock warrant expense					2,078,199
Loss on settlement of debt		613,926			1,364,339
Changes in operating assets and liabilities:
Accounts receivable		-			(3,463	)
Accounts payable		138,840			139,203	)
Accrued liabilities		656,958			486,373
Prepaid expenses and other current assets					(1,594
Net cash used in operating activities		(529,430	)		(597,962	)

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants		-			50,000
Payment of notes payable		(321,846	)
Proceeds from issuance of notes payable		875,000			657,000

Net cash provided by financing activities		553,154			707,000

Net decrease in cash and cash equivalents		23,724			109,038	)
Cash and cash equivalents at beginning of period		74,389			23,149
Cash and cash equivalents at end of period	$	98,113		$	132,817

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2017		March 31, 2016
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest	$	13,000	$	7,050

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Debt discount	$	50,000	$	-

Shares issued for debt and accrued interest	$	362,700	$	2,306,415

Shares issued for accounts payable and accrued expenses	$	339,339	$	-

Cashless exercise of warrants	$	165	$	-

Estimated loss on debt conversion	$	215,000	$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Immune Therapeutics, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2017

(Unaudited)

1. Organization and Description of Business

Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”).

On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc.

The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally.

In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products.

In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will determine whether or not to apply to obtain EMA benefits once funding becomes available.

In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom Inc. on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. At March 31, 2017, the Company’s equity interest had been further reduced to 13.3%, by subsequent issuances of Cytocom common stock to shareholders in settlement of notes payable.

In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.

Today, Immune Therapeutics is focused on the commercialization of affordable non-toxic immunotherapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other opportunistic infections for chronic often life-threatening diseases through the mobilization of the body’s immune system in Emerging Nations using existing clinical data.

Cytocom Inc, is a clinical-stage pharmaceutical company focused on the development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer and is responsible for the development of our patented therapies with the FDA and EMA.

As of this date, neither we nor our collaboration partners are permitted to market our drug candidates in the United States until we receive approval of a New Drug Application from the FDA. Neither we nor our collaboration partners have submitted an application for or received marketing approval for any of our drug candidates. Obtaining approval of an NDA can be a lengthy, expensive and uncertain process.

Going Concern

The Company experienced a net loss from operations of $2,705,933, and used cash and cash equivalents for operations in the amount of $529,430 during the quarter ended March 31, 2017, resulting in stockholder’s deficit of $10,289,063 at that date.

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through the sale of products, additional private or public debt or equity offerings, and it may also seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at March 31, 2017 was not sufficient to meet the cash requirements to fund planned operations through March 31, 2018 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2016 (including the notes thereto) set forth in Form 10-K.

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2016. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Revenue Recognition

We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. This standard permits early adoption and permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the potential impact of this standard on our financial position and results of operations, as well as our selected transition method. Based on our preliminary assessment, we believe the new standard will not have a material impact on our financial position and results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2017, the Company has no cash balances in excess of insured limits.

Segment and Geographic Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.

Fair Value of Financial Instruments

In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Fair Value Measurements

The ASC Topic 820, Fair Value Measurement, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer’s creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.

Fixed Assets

Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the three months ended March 31, 2017 and March 31, 2016 was $144 and $547, respectively.

Intangible Assets

Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of ten to sixteen years. Intangible assets are stated at the lower of cost or estimated fair value. During the years ended December 31, 2016 and December 31, 2015, the Company capitalized $nil and $nil respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10). Amortization expense for the three months ended March 31, 2017 and March 31, 2016 was $0 and $0, respectively.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. In 2015, the Company determined that the carrying amount recorded for the acquisition of licenses and patents related to LDN were impaired, and recorded an impairment loss of $5,226,352. No such impairment charges were recorded in 2016 or the first quarter of 2017.

Research and Development Costs

Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes

The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2017 and 2016, the Company does not have a liability for unrecognized tax uncertainties.

The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2017, and 2016, the Company has not accrued any interest or penalties related to uncertain tax positions.

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

Non-controlling Interest

In accordance with ASC Topic 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

A calculation of basic net loss per share follows:

	For the three months ended March 31,
	2017			2016
Historical net loss per share:
Numerator
Net loss	$	(2,705,933	)	$	(6,645,402	)
Non-controlling interest		(136,563	)		(44,120	)
Net loss attributed to Common stockholders	$	(2,569,370	)	$	(6,601,282	)

Denominator
Weighted-average common shares outstanding—Denominator for basic net loss per share		259,291,541			190,923,381
Basic net loss per share attributed to common stockholders	$	(0.01	)	$	(0.03	)

The Company’s potential dilutive securities, which include warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:

	For the three months ended March 31,
	2017		2016
Warrants to purchase Common stock		52,525,237		24,731,500

Recent Accounting Standards

During the quarter ended March 31, 2017, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

3. Fixed Assets

	March 31, 2017			December 31, 2016
Fixed Assets:
Computer equipment	$	9,738		$	9,738
Less accumulated depreciation		(8,032	)		(7,888	)
Property and equipment, net	$	1,706		$	1,850

The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

4. Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2017		December 31, 2016

Accrued payroll to officers and others	$	1,272,703	$	1,126,261
Accrued interest and penalties - notes payable		2,412,535		1,902,018
Estimated legal settlement		128,087		128,087
Other accrued liabilities		167,092		393

Total accrued expenses and other liabilities	$	3,980,417	$	3,156,759

5. Notes Payable

Notes payable consist of the following:

	March 31, 2017		December 31, 2016
Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earns interest at a rate of 18% per annum.	$	100,000	$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at March 31, 2017, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders.		286,000		286,000

Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and September 30, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $591,494 were in default at March 31, 2017, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders.		704,494		704,494

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.		425,000		425,000

Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.		100,000		100,000

Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended March 31, 2017.		-			554,882

Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default.		112,737			112,737

Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default.		50,000			50,000

Promissory note issued in July 2016 with an original issuance discount of $30,000. Net proceeds were $150,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default.		180,000			180,000

Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,641.88. The note was in default on March 31, 2017.		95,061			120,987

Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on September 30, 2017.		256,000			256,000

Notes aggregating $1,354,000 were issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017.		1,354,000			1,354,000

Notes aggregating $500,000 were issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018.		500,000			-

Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017.		50,000			-

Promissory note issued February 28, 2017, originally for $675,000, convertible into common stock of the Company in accordance with the conversion provisions of the note. In March 2017, $112,700 of the note was converted into 5 million common shares of the Company.		562,300			-

Less: Original issue discounts on notes payable and warrants issued with notes.		(33,333	)		(18,681	)

Total		4,742,259			4,225,419

Less: Current Portion	$	(4,742,259	)	$	(4,225,419	)

Long-Term debt, less current portion	$	-		$	-

As of March 31, 2017, the Company had accrued $2,412,535 in unpaid interest and default penalties. During the quarter ended March 31, 2017, 17,510,638 shares with a fair value of $809,925 were issued by the Company for settlement of promissory notes.

6. Capital Structure—Common Stock and Common Stock Purchase Warrants

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

As of March 31, 2017 and 2016, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.

As of March 31, 2017, the Company had 275,640,678 shares of common stock outstanding, and 250,428,133 outstanding as of December 31, 2016.

Stock Warrants

In the quarter ended March 31, 2017, there were no new warrants issued by the Company.

There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2017 and 2016.

Following is a summary of outstanding stock warrants at March 31, 2017 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2016		59,191,904	$	0.03-15.00	$	0.35

Issued in 2017		-	$	-	$	-

Expired and forfeited		5,010,220	$	0.03	$	0.03

Exercised		1,656,447	$	0.03	$	0.03

Warrants as of March 31, 2017		52,525,237	$	0.03-15.00	$	0.39

Summary of outstanding warrants as of March 31, 2017:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)

Fourth Quarter 2017		350,000	$	1.50-9.00		0.50
First Quarter 2018		127,500	$	15.00		0.75
Second Quarter 2018		33,334	$	15.00		1.00
Third Quarter 2018		250,000	$	1.50		1.25
Fourth Quarter 2018		6,089,166	$	1.00-1.50		1.50
First Quarter 2019		4,024,000	$	0.50-2.00		1.75
Second Quarter 2019		135,000	$	0.07-0.23		2.00
Third Quarter 2019		260,000	$	0.50-1.50		2.25
Fourth Quarter 2019		400,000	$	0.14		2.50
Second Quarter 2020		300,000	$	0.50		3.00
Fourth Quarter 2020		1,000,000	$	0.20		3.50
First Quarter 2021		12,600,000	$	0.20		3.75
Second Quarter 2021		23,806,237	$	0.03-0.20		4.00
Third Quarter 2021		3,150,000	$	0.15-0.20		4.25

7. Stock Compensation

Shares Issued for Services

During the quarters ended March 31, 2017 and 2016, the Company issued 6,045,460 and 19,043,000 shares of common stock respectively for consulting fees. The Company valued these shares at $365,455 and $1,314,169 respectively, based upon the fair market value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $365,834 and $669,667 for the quarters ended March 31, 2017 and 2016.

8. Income Taxes - Results of Operations

There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2017 and 2016 because the Company incurred a net loss in both quarters.

The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2016. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.

Our effective tax rate for fiscal years 2016 and 2015 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year.

As of December 31, 2016, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $79,900,000, which will expire in 2032-2035.

9. Licenses and Supply Agreements

Patent and Subsidiary Acquisition

The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.

In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors.

At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000.

Patent License Agreements

On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes.

On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384.

The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017. As of March 31, 2017, the Company had not made a commercial sale of licensed product. Under the Smith Agreement, if the licensors determine that the Company has not fulfilled its obligations, they may furnish the Company with written notice of such determination, in which case the Company must either fulfill the obligation or negotiate a mutually acceptable revised commitment. As of the date of the filing of this Form 10-Q, the licensors had not provided any such notice of determination under the agreement.

The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days’ after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.

The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs.

As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND.

On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement.

On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”).

The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016. As of March 31, 2017, the Company had not made a commercial sale of licensed product. Under the Foundation Agreement, if the licensor determines that the Company has not fulfilled its obligations, it may furnish the Company with written notice of such determination, in which case the Company must either fulfill the obligation or negotiate a mutually acceptable revised commitment. As of the date of the filing of this Form 10-Q, the licensor had not provided any such notice of determination under the agreement.

The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees.

The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs.

The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.

In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days’ written notice to Professor Shan.

On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

10. Commitments and Contingencies

Malawi Treatment Facilities

On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases.

In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct two trials involving Lodonal™ in Malawi:

a.	The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The PMPB approved the trial in late 2016 and recruitment began in late 2016 and continued through first quarter of 2017, with the trial now ongoing.

b.	The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The Company has put this trial on hold as it may not be necessary with the approval in Nigeria in addition to the pending approval in Kenya and Senegal for Lodonal™ for the treatment of cancer.

Distribution Agreements in Nigeria

Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria.

The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted.

In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The agreement expires in December 2018. The Company expects to implement the agreement in 2017, upon receipt of approvals from NAFDAC for the sale of Lodonal^TMin Nigeria. Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.

In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote Lodonal^TMupon execution of a definitive agreement between the companies and receipt of NAFDAC and other approvals to distribute Lodonal^TMin Nigeria.

Agreements with Hubei Qianjiang Pharmaceutical Company

On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account.

On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following:

Exploratory Toxicology (nGLP)

	●	Dose range finding studies
	●	Different species and methods of administration
	●	Multiple dosing regimens
	●	Estimate the response vs. dose given

Definitive Toxicology (GLP)

	●	Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)
	●	General toxicology studies
	●	Different species and methods of administration
	●	Immunogenicity study with NHPs

Special Toxicology Studies (planned)

Pursuant to the Amendment, Qianjiang Pharmaceutical has made certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States in 2016. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China.

In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein.

In December of 2016 Qianjiang Pharmaceutical completed the following documents:

Exploratory Toxicology (nGLP)

	●	Dose range finding studies
	●	Different species and methods of administration
	●	Multiple dosing regimens
	●	Estimate the response vs. dose given

Definitive Toxicology (GLP)

	●	Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)
	●	General toxicology studies
	●	Different species and methods of administration
	●	Immunogenicity study with NHPs

In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK.

Contract Manufacturing Agreements

On May 16, 2016, the Company entered into an agreement with Complete Pharmacy and Medical Solutions, LLC (“CPMS”) to compound, package and distribute the LDN tablets, capsules and/or creams in the United States. The initial term of the agreement is three years, with the option to renew for an additional year. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach, provided however that if the Company terminates the agreement, the Company will be required to reimburse CPMS for all unused packaging materials for the LDN, which unused packaging materials CPMS will provide to IMUN. If CPMS does not receive and ship at least 1,000 orders (prescriptions) during the term of the agreement, the Company will be required to reimburse CPMS for 100% of the “ramp up costs” (defined as all costs and expenses of labor and materials related to the testing, and required FDA and other governmental documentation/approvals of test data) of providing and producing the LDN, even where the Company cancels/terminates the agreement, which provision shall survive the cancellation/termination of the agreement.

On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”) entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms.

In January of 2017, Acromax obtained from the Ministry of Public Health and Social Assistance a Medications and Specialized Pharmaceuticals Registration Certification for Lodonal^TM, which allows for the manufacture and sale of Lodonal^TM in the Dominican Republic and for export. The Ministry also issued a Certificate of Pharmaceutical Product for Nigeria, Kenya, Senegal and Malawi, which will allow for the export of Lodonal^TM to those countries where we have drug and marketing approval.

Operating Leases

At March 31, 2017, the Company was a party to an agreement to lease office space in Orlando, Florida. Rent expense for the quarters ended March 31, 2017 and 2016 was $4,129 and $(114,794), respectively. The 2016 expense reflects the reversal of accruals for rent expense in prior years, including the settlement with E.J. Krause & Associates, Inc.

Legal Proceedings

None.

11. Subsequent Events

The Company issued 28,500,000 shares of common stock between March 31, 2017 and May 12, 2017, of which, 13,000,000 shares are for consulting fees, 5,500,000 shares are for debt conversions and settlements and 10,000,000 shares were sold for cash.

On April 4, 2017, the Company entered into a settlement agreement (the “Settlement Agreement”) with Mr. Marshall Faulk (“Faulk”). Pursuant to the Settlement Agreement, Faulk agreed to assign a promissory note issued by the Company to Faulk on December 10, 2015 in the principal amount of $100,000.00 (the “Prior Note”), under which the Company was in default, to Mr. Robert J. Dailey (“Dailey”) pursuant to a Debt Purchase and Exchange Agreement (the “Exchange Agreement”) between the parties. In addition, Faulk agreed to waive all claims against the Company relating to the Prior Note. In consideration for the foregoing, the Company agreed to issue Faulk 2,000,000 restricted common shares.

On May 1, 2017, the Company issued a warrant to purchase 1,500,000 shares of the Company’s common stock, at an exercise price of $0.15 per share. The warrant expires on May 1, 2022.

As of May 12, 2017, the Company had outstanding 304,140,678 shares of common stock.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Forward-Looking Statements and Associated Risks

This section and other parts of this Form 10-Q contain forward-looking statements. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements also can be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K/A for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 31, 2017 (the “2016 Form 10-K”) under the heading “Risk Factors”.

The following discussion should be read in conjunction with the 2016 Form 10-K and the consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. All information presented herein is based on the Company’s fiscal calendar. Unless otherwise stated, references in this report to particular years, quarters, months or periods refer to the Company’s fiscal years ended in December and the associated quarters, months, or periods of those fiscal years. Each of the terms the “Company”, “we”, “us” or “our” as used herein refers collectively to Immune Therapeutics, Inc. and its subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

General

In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available.

Research and Development

The Company’s research and development (“R&D”) activities commenced in the third quarter of 2012, the Company having completed the initial acquisition of MENK-related patents required for research in the second quarter of that year. Through 2013 and the first nine months of 2014, we continued to build R&D organization and capabilities focusing primarily on new uses for opioid-related immuno-therapies, such as LDN and MENK. Those activities were suspended at the end of September 2014, due to lack of funding. We expect to be able to resume activities in 2017.

Our R&D priorities include development of IRT-101 or MENK, a small synthetic peptide that is naturally occurring in the body, and IRT-103 LDN, an opioid receptor antagonist. Our pipeline provides two therapies with a wide range of indications that can be pursued. We believe that both molecules have the ability to stimulate the immune system in order to treat a variety of autoimmune diseases including multiple sclerosis, immune disorders such as Crohn’s disease, cancer, and viral infections such as HIV/AIDS.

Three Months Ended March 31, 2017 Compared to Three Months Ended March 31, 2016

Revenues

We had no revenues from operations for the three months ended March 31, 2017, compared to $3,463 for the three months ended March 31, 2016.

Operating Expenses

Selling, general and administrative

Selling, general and administrative expenses and related percentages for the three months ended March 31, 2017 and 2016 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017			2016
Selling, general and administrative	$	666		$	939
Increase/(decrease) from prior year	$	(273	)	$	537
Percent increase/(decrease) from prior year		(29	)%		134	%

For the three months ended March 31, 2017 and 2016, selling, general and administrative expenses were made up as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017		2016
Stock listing and investor relations expenses	$	10	$	49
Consulting and contractors		189		324
Payroll		226		396
Professional fees		108		85
Travel		12		19
Other expenses		121		66

In the three months ended March 31, 2017, total cash and cash accruals for selling, general and administrative expense was $666 compared to $939 for the corresponding period in 2016, a decrease of $273 or 29%. Significant cash items included:

	●	consulting and contractor services obtained to assist the Company in raising capital, manage investor relations, and develop business in new markets, in the amount of $189 in 2017, a decrease of $135 or 42% over the $324 spent in 2016. The decrease was the result primarily of the expiration of certain consulting contracts by the end of 2016 and a one-time charge of $95 in 2016 for consulting fees owed from prior periods;

	●	professional fees for legal, tax and accounting services in the amount of $108 in 2017, an increase of $23 or 27% over the $85 spent in 2016. The increase was primarily due to costs incurred for increased borrowing in the first quarter of 2017 and higher fees paid for audit and tax services in the first quarter of 2017;

	●	payroll in the amount of $226 in 2017, a decrease of $170 or 43% over the $396 spent in 2016. The decrease reflects lower headcount in 2017, and the costs of stock awards to executives and employees in the first quarter of 2016. There were no stock awards in the first quarter of 2017; and

	●	travel in the amount of $12 in 2017, a decrease of $7 or 39% over the $19 spent in 2016.

Research and development

R&D expenses and related percentages for the three months ended March 31, 2017 and 2016 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017			2016
Research and development	$	119		$	(19	)
Increase from prior year	$	138		$	(196	)
Percent increase/(decrease) from prior year		100	%		(111	)%

Expenses for research and development in the three months ended March 31, 2017 increased by 100% compared to expenses in the same period in 2016. The increase reflects a one-time reversal of accrued expenses ($55) in 2016 for the development of an application to monitor LDN treatment, and increased legal fees in 2017 to maintain patents and licenses, offset by lower travel expenses for R&D activities in Africa.

Significant items included:

	●	payments for contracted technical services, $25 in 2017, an increase of $44 or 100% over the $(19) spent in 2016, reflecting a one-time reversal of accrued expenses ($55) in 2016 for the development of an application to monitor LDN treatment;

	●	payments for professional fees of $39 in 2017, an increase of $17 or 79% over the $22 spent in 2016, reflecting the increased cost in maintaining patents and licenses worldwide;

	●	payroll of $0 in 2017, an increase of $5 or 100% over the $(5) credit in 2016. In 2016, the Company reversed charges it had accrued in prior periods for payroll tax liabilities.

Most of the R&D spending in the first quarter of 2017 was for LDN. In the same period in 2016 75% of the spending was for the development of LDN; the balance was spent on MENK.

Stock issued for services

The Company periodically receives services from consultants under long-term consulting contracts, in terms of which it issues stock to prepay for the services. In such cases, the Company initially accounts for the full cost of these services as Prepaid Services on its balance sheet, calculated by the number of shares issued multiplied by the share price on the contract date. This amount is then amortized as a cost over the period in which the services are provided to the Company. The Company reports these costs separately from Selling, general and administrative costs, and Research and development costs, to better demonstrate the true costs of Selling, general and administrative activities, and Research and development.

Amortization of amounts recorded as Prepaid Services for stock issued for services G&A and related percentages for the three months ended March 31, 2017 and 2016 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017			2016
Amortization of prepaid consulting expense G&A	$	481		$	670
Percentage decrease from prior year		(28	)%		(69	)%

The decline in expense reflects the decrease in the price of the Company’s stock year over year and the fact that the cost of shares issued for services had been fully amortized in prior years.

The number of shares issued for prepaid consulting services G&A in the three months ending March 31, 2017 was 6,045,460 (19,043,000 in the corresponding period in 2016).

Prepaid consulting services G&A in the three months ended March 31, 2017 consisted of the following:

Amortization of cost of stock issued prior to 2016	$	5
Amortization of cost of stock issued in 2016		261
Amortization of cost incurred for new stock issued in the three months ended March 31, 2017 under consulting contracts entered into in 2017		215

Warrant valuation expense

When the Company sells its stock for cash or settles debt for stock, it periodically issues warrants to acquire additional stock at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model (see above 6. Capital Structure—Common Stock and Common Stock Purchase Warrants.) This expense is reported in the Condensed Consolidated Statements of Operations above as the Warrant valuation expense.

In the three months ended March 31, 2017, the Company issued no warrants to stockholders. In the three months ended March 31, 2016, the Company issued 15,600,000 warrants to stockholders at an exercise price range of $0.20 to $2.00, for which it recorded an expense of $2,078.

Depreciation and amortization

The Company amortizes the costs incurred to acquire patents and licenses over the period of the related agreements. The decrease year over year in depreciation and amortization expense reflects the fact that all of the Company’s patents and licenses had been fully amortized by December 31, 2016.

Depreciation and amortization expenses for the three months ended March 31, 2017 and 2016 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017			2016
Depreciation expense	$	-		$	1
Amortization expense	$	-		$	-
Decrease from prior year	$	(1	)	$	(148	)
Percentage increase/(decrease) from prior year		(100	)%		(100	)%

Interest Expense

Interest expense for the three months ended March 31, 2017 and 2016 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2017			2016
Interest expense	$	576		$	301
Increase from prior year	$	275		$	283
Percentage increase from prior year		91	%		1,571	%

The increase in interest expense reflects the higher level of notes payable outstanding at March 31, 2017 ($4,742) than compared to March 31, 2016 ($2,838).

Loss on settlement of debt

In three months ended March 31, 2017, certain lenders to the Company settled all or a portion of their notes or accounts payable by converting them to equity. The Company recorded an expense of $614, reflecting the fair value of the shares of common stock issued in exchange for the debt. In three months ended March 31, 2016, the Company recorded an expense of $1,364, reflecting the fair value of the shares of common stock issued in exchange for the debt.

Liquidity

Liquidity is measured by our ability to secure enough cash to meet our contractual and operating needs as they arise. We do not anticipate generating sufficient net positive cash flows from our operations to fund the next twelve months. We had cash of $98,113 at March 31, 2017, compared to $132,187 at March 31, 2016.

For the three months ended March 31, 2017 and 2016, net cash used in operating activities from operations was $529,430 and $497,962, respectively.

No cash was used in investing activities for the three months ended March 31, 2017 and 2016.

During the three months ended March 31, 2017 proceeds from the sale of stock and exercise of stock warrants totaled $0 compared to $50,000 for the corresponding period in 2016. We also received $875,000 from the issuance of notes payable in three months ended March 31, 2017, compared to $657,000 in 2016. There were $321,846 of loan repayments made in cash in the three months ended March 31, 2017 ($0 in 2016).

The Company expects to generate revenues from sales in 2017. If the Company is unable to generate sufficient cash flows from sales, or if it does not raise additional working capital to meet all of its operating obligations and expenditures, the Company may have to modify its business plan.

In addition to the cost of its ongoing operations, the Company expects it will incur future research and development expenditures in the next 12 months through Cytocom. Cytocom plans to conduct Phase II and Phase IIB trials for the treatment of Crohn’s disease, at an estimated cost of $3,900,000 and $7,500,000 respectively for each phase. If the trials do not commence before the end of 2017, the Company will be required to make a payment of $100,000 in December 2017 under its license agreements. In prior years, the Company has been able to raise funds through sales of notes payable to cover this obligation, and it expects to do the same if the payment becomes due in December 2017.

Off-Balance Sheet Arrangements

During the three months ended March 31, 2017 and 2016, we did not engage in any off balance sheet arrangements as defined in item 303(a)(4) of the SEC’s Regulation S-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of our disclosure controls and procedures as defined in Rules 13(a)-15(e) under the Exchange Act. Based on this evaluation, the principal executive officer and principal financial officer concluded that, because of the weakness in internal controls over financial reporting described below, our disclosure controls and procedures are ineffective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Management assessed the effectiveness of the internal controls over financial reporting as of March 31, 2017, using the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this assessment, our management concluded that, as of March 31, 2017, the internal controls over financial reporting were not effective. The reportable conditions and material weakness relate to a limited segregation of duties and lack of an audit committee. The limited segregation of duties within our company and the lack of an audit committee are due to the small number of employees. Management has determined that this control deficiency constitutes a material weakness. This material weakness could result in material misstatements of significant accounts and disclosures that would result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

Going forward, management anticipates that additional staff will be necessary to mitigate these weaknesses, as well as to implement other planned improvements. Additional staff will enable us to document and apply transactional and periodic controls procedures, permit a better review and approval process and improve quality of financial reporting. However, the potential addition of new staff is contingent on obtaining additional financing, and there is no assurance that we will be able to do so.

Limitations on the Effectiveness of Internal Controls

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The legal proceedings described in Note 11 of the “Notes to the Condensed Consolidated Financial Statements” are incorporated in this “Item 1: Legal Proceedings” by reference.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In the quarter ended March 31, 2017, the Company issued a total of 25,212,545 shares of common stock (net of stock cancellations). 17,510,638 of those shares were issued to settle amounts owed under notes payable, including accrued and unpaid interest as applicable, to common stock as repayment of the notes (8,503,041 in 2016). No shares were issued to settle amounts owed to certain of the Company’s vendors and employees (2,418,942 in 2016). Between January 1, 2017 and March 31, 2017, a warrant holder exercised 1,656,447 warrants in a cashless exercise to purchase shares (0 between January 1, 2016 and March 31, 2016). The Company sold no shares of its common stock. In total, the Company received $0 as consideration for the exercise of the previously-issued warrants and $0 for the purchase of common stock, for an aggregate sum of $0 (between January 1, 2016 and March 31, 2016, it sold an aggregate 312,500 shares of its common stock at $0.08 per share. In total, the Company received $0 as consideration for the exercise of the previously-issued warrants and $25,000 for the purchase of common stock, for an aggregate sum of $25,000).

The following table lists all securities issued during in the three months ended March 31, 2017 without registering the securities under the Securities Act of 1933, as amended (the “Securities Act”):

Date

Description

Number

Purchaser

Proceeds

Consideration

Exemption

1/10/2017

Common Stock Purchase

500,000

Consultant

Nil

Advisory Services

Sec. 4(a)(2)

1/25/17

Common Stock Purchase

5,000,000

Consultant

Nil

Advisory Services

Sec. 4(a)(2)

2/24/17

Common Stock Purchase

272,730

Consultant

Nil

Advisory Services

Sec. 4(a)(2)

2/24/2017

Common Stock Purchase

272,730

Consultant

Nil

Advisory Services

Sec. 4(a)(2)

2/15/2017

Common Stock Purchase

1,656,447

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/31/2017

Common Stock Purchase

950,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

2/10/2017

Common Stock Purchase

2,500,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/2/2017

Common Stock Purchase

1,500,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/13/2017

Common Stock Purchase

1,500,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/21/2017

Common Stock Purchase

1,500,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/28/2017

Common Stock Purchase

2,500,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/28/2017

Common Stock Purchase

2,060,638

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/10/2017

Common Stock Purchase

3,000,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/31/2017

Common Stock Purchase

2,000,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

The issuances of the Company’s securities were completed in private transactions by the Company not involving any public offering pursuant to Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”). The shares purchased pursuant to the warrant exercises and the shares purchased were issued bearing restrictive legend and may not be resold by the purchasers unless such securities are registered or an exemption from registration is available. The Company determined, based on representations of the investors, that the investors were “accredited investors” as defined under Rule 501(a) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

The current portion of notes payable on the Company’s Condensed Consolidated Balance Sheets above contains, at March 31, 2017, certain promissory notes on which the Company was in arrears on payments of principal as follows:

1.	Repayment of a promissory note for $50,000 issued in July 2016. The lender earns interest at a rate of 6% per month. The note is repayable on December 31, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender.

2.	Payment of principal aggregating $286,000 on certain promissory notes issued between November 26, 2014 and September 30, 2016, to raise up to $2,000,000 in debt, on which lenders earn interest at a rate of 10% per annum, plus a pro-rata share of 2 percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity.

3.	Payment of principal aggregating $591,494 on certain promissory notes issued between May 1, 2016 and September 30, 2016, and maturing between June 14, 2016 and December 31, 2016. Interest is payable in a fixed amount not tied to a specific interest rate.

4.	Repayment of promissory notes for $112,737 issued in November 2016. The lender earns interest at a rate of 10% per annum. The note is repayable on November 3, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender.

5.	Repayment of a promissory note for $100,000 issued in December 2015. The lender earns interest at a rate of 10% per month. The Company is obligated to pay late-payment penalties totaling $5,000 per day. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.

6.	Repayment of promissory notes for $95,061 issued in August 2016. The lender earns interest at a rate of 5% per annum. The notes are payable in 18 equal monthly installments of $8,641. The notes are in default, although no demand for repayment has been made by the lender.

7.	Payment of principal aggregating $425,000 on certain promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes matured on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.

At March 31, 2017, the Company had insufficient cash on hand to repay these notes.

ITEM 6. EXHIBITS

Exhibit Number		Name of Exhibit

31.1		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.

10.43		Securities Purchase Agreement with Ira Gaines.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Immune Therapeutics, Inc.

Date: May 12, 2017	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer

	Immune Therapeutics, Inc.

Date: May 12, 2017	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer

EX-31.1 2 ex31-1.htm

CERTIFICATION

I, Noreen Griffin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Immune Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15I and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting..

Date: May 12, 2017	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

I, Peter Aronstam, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Immune Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2017	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 3 ex32-1.htm

CERTIFICATION

(2)

In connection with the periodic report of Immune Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), we, Noreen Griffin, Chief Executive Officer (Principal Executive Officer) and Peter Aronstam, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of our knowledge:1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: May 12, 2017	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-101.INS 4 imun-20170331.xml XBRL INSTANCE FILE 0001559356 2017-01-01 2017-03-31 0001559356 2017-03-31 0001559356 2015-12-31 0001559356 2016-12-31 0001559356 IMUN:CytocomIncMember 2014-12-07 2014-12-08 0001559356 IMUN:CytocomIncMember 2013-01-01 2013-12-31 0001559356 IMUN:NotesPayableOneMember 2017-03-31 0001559356 IMUN:NotesPayableTwoMember 2017-03-31 0001559356 IMUN:NotesPayableThreeMember 2017-03-31 0001559356 IMUN:NotesPayableFourMember 2017-03-31 0001559356 IMUN:NotesPayableFiveMember 2017-03-31 0001559356 IMUN:NotesPayableSixMember 2017-03-31 0001559356 IMUN:NotesPayableSevenMember 2017-03-31 0001559356 IMUN:NotesPayableEightMember 2017-03-31 0001559356 IMUN:NotesPayableOneMember 2016-12-31 0001559356 IMUN:NotesPayableTwoMember 2016-12-31 0001559356 IMUN:NotesPayableThreeMember 2016-12-31 0001559356 IMUN:NotesPayableFourMember 2016-12-31 0001559356 IMUN:NotesPayableFiveMember 2016-12-31 0001559356 IMUN:NotesPayableSixMember 2016-12-31 0001559356 IMUN:NotesPayableSevenMember 2016-12-31 0001559356 IMUN:NotesPayableEightMember 2016-12-31 0001559356 IMUN:IraGainesMember 2014-07-28 2014-07-29 0001559356 IMUN:IraGainesMember 2014-07-29 0001559356 2015-09-30 0001559356 IMUN:LendersMember 2017-03-31 0001559356 IMUN:LendersMember IMUN:MayOneTwoThousandFifteenMember 2016-12-31 0001559356 IMUN:LendersMember us-gaap:MinimumMember 2016-12-31 0001559356 IMUN:LendersMember us-gaap:MaximumMember 2016-12-31 0001559356 IMUN:LendersOneMember 2017-03-31 0001559356 IMUN:CytocomIncMember us-gaap:MinimumMember IMUN:AprilTwentyNineTwoThousandFifteenMember 2015-12-31 0001559356 IMUN:CytocomIncMember us-gaap:MaximumMember IMUN:AprilTwentyNineTwoThousandFifteenMember 2015-12-31 0001559356 IMUN:LendersThreeMember 2015-12-31 0001559356 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001559356 IMUN:FourthQuarter2020Member 2017-01-01 2017-03-31 0001559356 IMUN:FourthQuarter2017Member 2017-01-01 2017-03-31 0001559356 IMUN:FirstQuarter2018Member 2017-01-01 2017-03-31 0001559356 IMUN:SecondQuarter2018Member 2017-01-01 2017-03-31 0001559356 IMUN:ThirdQuarter2018Member 2017-01-01 2017-03-31 0001559356 IMUN:FourthQuarter2018Member 2017-01-01 2017-03-31 0001559356 IMUN:FirstQuarter2019Member 2017-01-01 2017-03-31 0001559356 IMUN:SecondQuarter2019Member 2017-01-01 2017-03-31 0001559356 IMUN:ThirdQuarter2019Member 2017-01-01 2017-03-31 0001559356 IMUN:FourthQuarter2019Member 2017-01-01 2017-03-31 0001559356 IMUN:SecondQuarter2020Member 2017-01-01 2017-03-31 0001559356 IMUN:FourthQuarter2020Member 2017-03-31 0001559356 IMUN:FourthQuarter2017Member 2017-03-31 0001559356 IMUN:FirstQuarter2018Member 2017-03-31 0001559356 IMUN:SecondQuarter2018Member 2017-03-31 0001559356 IMUN:ThirdQuarter2018Member 2017-03-31 0001559356 IMUN:FourthQuarter2018Member 2017-03-31 0001559356 IMUN:FirstQuarter2019Member 2017-03-31 0001559356 IMUN:SecondQuarter2019Member 2017-03-31 0001559356 IMUN:ThirdQuarter2019Member 2017-03-31 0001559356 IMUN:FourthQuarter2019Member 2017-03-31 0001559356 IMUN:SecondQuarter2020Member 2017-03-31 0001559356 IMUN:YoungAgreementMember IMUN:DrBernardBihariMember 2012-08-12 2012-08-13 0001559356 IMUN:YoungAgreementMember 2013-01-01 2013-12-31 0001559356 IMUN:YoungAgreementMember 2013-12-31 0001559356 IMUN:SmithAgreementMember 2012-12-23 2012-12-24 0001559356 IMUN:SmithAgreementMember IMUN:InitialLicenseFeeMember 2012-12-23 2012-12-24 0001559356 IMUN:SmithAgreementMember IMUN:ExpensesMember 2012-12-23 2012-12-24 0001559356 IMUN:ShanAgreementMember 2013-05-01 2013-05-31 0001559356 IMUN:AgreementswithHubeiQianjiangPharmaceuticalCompanyMember 2012-10-17 2012-10-18 0001559356 us-gaap:CommonStockMember 2016-12-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001559356 IMUN:StockToBeIssuedMember 2016-12-31 0001559356 us-gaap:RetainedEarningsMember 2016-12-31 0001559356 us-gaap:NoncontrollingInterestMember 2016-12-31 0001559356 2016-01-01 2016-03-31 0001559356 IMUN:NotesPayableNineMember 2016-12-31 0001559356 IMUN:NotesPayableTenMember 2016-12-31 0001559356 IMUN:NotesPayableNineMember 2017-03-31 0001559356 IMUN:NotesPayableTenMember 2017-03-31 0001559356 us-gaap:WarrantMember 2016-12-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2016-12-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2016-12-31 0001559356 IMUN:FirstQuarter2021Member 2017-01-01 2017-03-31 0001559356 IMUN:FirstQuarter2021Member 2017-03-31 0001559356 IMUN:NotesPayableElevenMember 2016-12-31 0001559356 IMUN:CytocomIncMember IMUN:AprilTwentyNineTwoThousandFifteenMember 2015-01-01 2015-12-31 0001559356 2015-11-03 0001559356 2015-11-02 2015-11-03 0001559356 IMUN:CPMSMember 2017-01-01 2017-03-31 0001559356 IMUN:NotesPayableTwelveMember 2016-12-31 0001559356 IMUN:NotesPayableThirteenMember 2016-12-31 0001559356 IMUN:NotesPayableFourteenMember 2016-12-31 0001559356 IMUN:NotesPayableFifteenMember 2016-12-31 0001559356 IMUN:NotesPayableElevenMember 2017-03-31 0001559356 IMUN:NotesPayableTwelveMember 2017-03-31 0001559356 IMUN:NotesPayableThirteenMember 2017-03-31 0001559356 IMUN:NotesPayableFourteenMember 2017-03-31 0001559356 IMUN:NotesPayableFifteenMember 2017-03-31 0001559356 IMUN:LendersMember IMUN:MayOneTwoThousandFifteenMember 2016-01-01 2016-12-31 0001559356 2016-06-01 2016-06-02 0001559356 2016-07-31 0001559356 2016-07-30 2016-07-31 0001559356 2016-08-30 2016-08-31 0001559356 2016-08-31 0001559356 IMUN:LendersMember 2016-12-31 0001559356 IMUN:SecondQuarter2021Member 2017-01-01 2017-03-31 0001559356 IMUN:ThirdQuarter2021Member 2017-01-01 2017-03-31 0001559356 IMUN:SecondQuarter2021Member 2017-03-31 0001559356 IMUN:ThirdQuarter2021Member 2017-03-31 0001559356 IMUN:DrPlotnikoffMember 2012-04-20 2012-04-24 0001559356 IMUN:TNIIPManagementMember 2012-04-20 2012-04-24 0001559356 IMUN:TNIBioTechIPIncMember 2012-04-20 2012-04-24 0001559356 IMUN:SmithAgreementMember 2014-09-22 2014-09-24 0001559356 IMUN:ShanAgreementMember 2014-08-04 2014-08-06 0001559356 IMUN:DistributionAgreementAHARPharmaMember 2013-10-01 2013-10-31 0001559356 IMUN:PrepaidServicesMember 2016-12-31 0001559356 IMUN:IrishLimitedLiabilityMember 2014-03-01 2014-03-31 0001559356 IMUN:LendersMember 2016-01-01 2016-12-31 0001559356 IMUN:DecemberThirtyFirstTwoThousandSeventeenMember 2016-12-31 0001559356 IMUN:DecemberThirtyFirstTwoThousandSeventeenMember 2016-01-01 2016-12-31 0001559356 IMUN:CytocomIncMember 2016-04-01 2016-04-30 0001559356 IMUN:YoungAgreementMember IMUN:DrBernardBihariMember 2012-08-13 0001559356 2017-05-12 0001559356 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001559356 us-gaap:CommonStockMember 2017-03-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-03-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001559356 IMUN:StockToBeIssuedMember 2017-01-01 2017-03-31 0001559356 IMUN:StockToBeIssuedMember 2017-03-31 0001559356 IMUN:PrepaidServicesMember 2017-01-01 2017-03-31 0001559356 IMUN:PrepaidServicesMember 2017-03-31 0001559356 us-gaap:RetainedEarningsMember 2017-01-01 2017-03-31 0001559356 us-gaap:RetainedEarningsMember 2017-03-31 0001559356 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-03-31 0001559356 us-gaap:NoncontrollingInterestMember 2017-03-31 0001559356 IMUN:CytocomIncMember 2017-01-01 2017-03-31 0001559356 IMUN:PropertyAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001559356 IMUN:PropertyAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001559356 us-gaap:MinimumMember 2017-01-01 2017-03-31 0001559356 us-gaap:MaximumMember 2017-01-01 2017-03-31 0001559356 2016-03-31 0001559356 2016-01-01 2016-12-31 0001559356 IMUN:IntangibleAssetsMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001559356 IMUN:IntangibleAssetsMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001559356 2015-01-01 2015-12-31 0001559356 IMUN:MarchThirtyFirstTwoThousandEighteenMember 2017-03-31 0001559356 IMUN:MarchThirtyFirstTwoThousandEighteenMember 2017-01-01 2017-03-31 0001559356 IMUN:LendersMember 2017-01-25 0001559356 IMUN:LendersMember 2017-01-24 2017-01-25 0001559356 2017-02-27 2017-02-28 0001559356 us-gaap:WarrantMember 2017-03-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2017-03-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2017-03-31 0001559356 us-gaap:SubsequentEventMember 2017-05-12 0001559356 us-gaap:SubsequentEventMember 2017-05-11 2017-05-12 0001559356 us-gaap:SubsequentEventMember IMUN:ConsultingFeesMember 2017-05-11 2017-05-12 0001559356 us-gaap:SubsequentEventMember IMUN:DebtConversionMember 2017-05-10 2017-05-12 0001559356 us-gaap:SubsequentEventMember IMUN:SettlementAgreementMember IMUN:MrMarshallFaulkMember 2017-04-04 0001559356 us-gaap:SubsequentEventMember IMUN:SettlementAgreementMember IMUN:MrMarshallFaulkMember 2017-04-03 2017-04-04 0001559356 us-gaap:SubsequentEventMember 2017-05-01 0001559356 us-gaap:SubsequentEventMember 2017-04-29 2017-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure IMUN:Installments IMUN:Doses IMUN:Segment Immune Therapeutics, Inc. 10-Q 2017-03-31 false --12-31 Smaller Reporting Company

98113

23149

74389

132817

-10289063

-9124344

25043

360420026

962429

-365718976

-3990366

-822500

27564

361542431

1432883

-876666

-368288346

-4126929

0.0001

500000000

275640678

250428133

275640678

250428133

304140678

-2705933

-6645402

-2569370

-136563

250428133

275640678

113242522

140100000

500000

28500000

13000000

365834

17510638

809925

1751

808174

17510638

5500000

1656447 165 -165 2078199 365834 669667

144

547

-529430

-597962

656958

486373

553154

707000

50000

23724

109038

13000

7050

0.553 0.133 0.125

529430

1000000000

52525237

24731500

8032

7888

9738

2017-12-01

2016-09-30

2016-11-03

2017-09-30

2017-04-07

2017-09-30

2017-07-05

0.18

0.10

0.02

0.18

0.05

0.10

0.06

0.05

0.02

0.07

2000000

149854

100000

36 18

286000

591494

100000

1354000

500000

1656447

59191904

52525237

0.03 15.00 0.03 15.00 0.03 0.35 0.39 0.03

1000000

350000

127500

33334

250000

6089166

4024000

135000

260000

400000

300000

12600000

23806237

3150000

6045460

19043000

6045460

A calculation of basic net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(2,705,933</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(136,563</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,569,370</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstanding—Denominator for basic net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">259,291,541</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.01</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td></tr> </table>

-114794

5226352

3463

1516179

4983082

144

547

2078199 731288 1983837

118656

-18842

666091

939341

-1516179

-4979619

-1189754

-1665783

-613926

-1364339

575828

301444

259291541

190923381

-0.01

-0.03

-2569370

-6601282

-136563

-44120

875000

657000

150000

250000

35346

0.00

79900000

expire in 2032-2035.

3463

-33333

-18681

30000

2412535

1902018

809925

1.50

1.00

0.50

0.07

0.50

0.03

0.15

0.20

9.00

15.00

1.50

2.00

0.23

1.50

0.14

0.50

0.20

P3Y6M

P6M

P9M

P1Y

P1Y3M

P1Y6M

P1Y9M

P2Y

P2Y3M

P2Y6M

P3Y

P3Y9M

P4Y

P4Y3M

IMUN 2017 0001559356

P3Y

P5Y

P3Y

P5Y

8642

505994

365455

1314169

605

314396

470454

-420000

October 1, 2016 and January 31, 2017

between July 1, 2016 and December 31, 2016

November 1, 2017 and December 31, 2017

January 12, 2018 and March 31, 2018

365834

669667

365455 1314169

1594

138840

139203

-321846

0.15

the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. 0.06 2715000 500000

100019

76439

-4126929

-3990366

-6162134

-5133978

-368288346

-365718976

-876666 -822500 1432883 962429

361542431

360420026

27564

25043

10389082

9200783

10389082

9200783

4742259

4225419

3980417

3156759

1666406

1818605

100019

76439

200

1706

1850

98113

74389

expires on May 1, 2022 1.00

1272703

1126261

3980417

3156759

the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock.

167092

393

128087

4742259

4225419

100000

286000

704494

425000

100000

112737

50000

100000

286000

704494

425000

100000

554882

112737

50000

180000

120987

180000

95061

256000

1354000

256000

1354000

500000

50000

562300

198500

2412535

540000

300000

8000000

12250000

20250000

1000000

972000

2880384

16006000

98000000

270000

400000

1372000

118333

0.01

165384

100000

65384

50000 362700 2306415

339339

165 215000

P10Y

P16Y

259291541

190923381

-0.01

-0.03

112700

675000

5000000

5010220

0.03 0.03 P12M P24M

10000000

2000000

1500000 304140678

1. Organization and Description of Business   Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”).   On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc.   The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally.   In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products.   In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will determine whether or not to apply to obtain EMA benefits once funding becomes available.   In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom Inc. on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. At March 31, 2017, the Company’s equity interest had been further reduced to 13.3%, by subsequent issuances of Cytocom common stock to shareholders in settlement of notes payable.    In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.   Today, Immune Therapeutics is focused on the commercialization of affordable non-toxic immunotherapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other opportunistic infections for chronic often life-threatening diseases through the mobilization of the body’s immune system in Emerging Nations using existing clinical data.   Cytocom Inc, is a clinical-stage pharmaceutical company focused on the development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer and is responsible for the development of our patented therapies with the FDA and EMA.   As of this date, neither we nor our collaboration partners are permitted to market our drug candidates in the United States until we receive approval of a New Drug Application from the FDA. Neither we nor our collaboration partners have submitted an application for or received marketing approval for any of our drug candidates. Obtaining approval of an NDA can be a lengthy, expensive and uncertain process.   Going Concern   The Company experienced a net loss from operations of $2,705,933, and used cash and cash equivalents for operations in the amount of $529,430 during the quarter ended March 31, 2017, resulting in stockholder’s deficit of $10,289,063 at that date.   The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through the sale of products, additional private or public debt or equity offerings, and it may also seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at March 31, 2017 was not sufficient to meet the cash requirements to fund planned operations through March 31, 2018 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

2. Summary of Significant Accounting Policies   Basis of Presentation   The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2016 (including the notes thereto) set forth in Form 10-K.    The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2016. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.   Revenue Recognition   We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. This standard permits early adoption and permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the potential impact of this standard on our financial position and results of operations, as well as our selected transition method. Based on our preliminary assessment, we believe the new standard will not have a material impact on our financial position and results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions.   Leases   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.   Use of Estimates   The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.   Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.    Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2017, the Company has no cash balances in excess of insured limits.   Segment and Geographic Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.   Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.   Fair Value Measurements   The ASC Topic 820, Fair Value Measurement, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer’s creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.   Fixed Assets   Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the three months ended March 31, 2017 and March 31, 2016 was $144 and $547, respectively.   Intangible Assets   Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of ten to sixteen years. Intangible assets are stated at the lower of cost or estimated fair value. During the years ended December 31, 2016 and December 31, 2015, the Company capitalized $nil and $nil respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10). Amortization expense for the three months ended March 31, 2017 and March 31, 2016 was $0 and $0, respectively.    Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. In 2015, the Company determined that the carrying amount recorded for the acquisition of licenses and patents related to LDN were impaired, and recorded an impairment loss of $5,226,352. No such impairment charges were recorded in 2016 or the first quarter of 2017.   Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.   Income Taxes   The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2017 and 2016, the Company does not have a liability for unrecognized tax uncertainties.   The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2017, and 2016, the Company has not accrued any interest or penalties related to uncertain tax positions.   Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.    Non-controlling Interest   In accordance with ASC Topic 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.   Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.   A calculation of basic net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(2,705,933</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(136,563</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,569,370</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstanding—Denominator for basic net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">259,291,541</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.01</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td></tr> </table>   The Company’s potential dilutive securities, which include warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.   The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants to purchase Common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,525,237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Recent Accounting Standards   During the quarter ended March 31, 2017, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. This standard permits early adoption and permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the potential impact of this standard on our financial position and results of operations, as well as our selected transition method. Based on our preliminary assessment, we believe the new standard will not have a material impact on our financial position and results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions.    In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.

3. Fixed Assets   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fixed Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 115%">Computer equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">9,738</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">9,738</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(8,032</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(7,888</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">1,706</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">1,850</td> <td style="line-height: 115%"> </td></tr> </table>   The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

4. Accrued Liabilities   Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Accrued payroll to officers and others</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">1,272,703</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">1,126,261</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Accrued interest and penalties - notes payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,412,535</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,902,018</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Estimated legal settlement</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">128,087</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">128,087</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">167,092</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">393</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total accrued expenses and other liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,980,417</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,156,759</td> <td style="line-height: 115%"> </td></tr> </table>

5. Notes Payable   Notes payable consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%; text-align: justify; line-height: 115%">Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earns interest at a rate of 18% per annum.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at March 31, 2017, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">286,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">286,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and September 30, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $591,494 were in default at March 31, 2017, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">704,494</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">704,494</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">425,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">425,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,000</td> <td style="line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%; text-align: justify; line-height: 115%">Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended March 31, 2017.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 16%; text-align: right; line-height: 115%">554,882</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">112,737</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">112,737</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in July 2016 with an original issuance discount of $30,000. Net proceeds were $150,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">180,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">180,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,641.88. The note was in default on March 31, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">95,061</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">120,987</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on September 30, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Notes aggregating $1,354,000 were issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,354,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,354,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Notes aggregating $500,000 were issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued February 28, 2017, originally for $675,000, convertible into common stock of the Company in accordance with the conversion provisions of the note. In March 2017, $112,700 of the note was converted into 5 million common shares of the Company.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562,300</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Original issue discounts on notes payable and warrants issued with notes.</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(33,333</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(18,681</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,742,259</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,225,419</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Current Portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,742,259</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,225,419</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Long-Term debt, less current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>    As of March 31, 2017, the Company had accrued $2,412,535 in unpaid interest and default penalties. During the quarter ended March 31, 2017, 17,510,638 shares with a fair value of $809,925 were issued by the Company for settlement of promissory notes.

7. Stock Compensation   Shares Issued for Services   During the quarters ended March 31, 2017 and 2016, the Company issued 6,045,460 and 19,043,000 shares of common stock respectively for consulting fees. The Company valued these shares at $365,455 and $1,314,169 respectively, based upon the fair market value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $365,834 and $669,667 for the quarters ended March 31, 2017 and 2016.

8. Income Taxes - Results of Operations   There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2017 and 2016 because the Company incurred a net loss in both quarters.   The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2016. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.   Our effective tax rate for fiscal years 2016 and 2015 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year.   As of December 31, 2016, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $79,900,000, which will expire in 2032-2035.

9. Licenses and Supply Agreements   Patent and Subsidiary Acquisition   The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.   In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors.   At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000.   Patent License Agreements   On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes.    On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384.   The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017. As of March 31, 2017, the Company had not made a commercial sale of licensed product. Under the Smith Agreement, if the licensors determine that the Company has not fulfilled its obligations, they may furnish the Company with written notice of such determination, in which case the Company must either fulfill the obligation or negotiate a mutually acceptable revised commitment. As of the date of the filing of this Form 10-Q, the licensors had not provided any such notice of determination under the agreement.   The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days’ after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.   The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs.   As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND.   On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement.   On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”).    The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016. As of March 31, 2017, the Company had not made a commercial sale of licensed product. Under the Foundation Agreement, if the licensor determines that the Company has not fulfilled its obligations, it may furnish the Company with written notice of such determination, in which case the Company must either fulfill the obligation or negotiate a mutually acceptable revised commitment. As of the date of the filing of this Form 10-Q, the licensor had not provided any such notice of determination under the agreement.   The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees.   The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs.   The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.   In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days’ written notice to Professor Shan.   On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

11. Subsequent Events   The Company issued 28,500,000 shares of common stock between March 31, 2017 and May 12, 2017, of which, 13,000,000 shares are for consulting fees, 5,500,000 shares are for debt conversions and settlements and 10,000,000 shares were sold for cash.   On April 4, 2017, the Company entered into a settlement agreement (the “Settlement Agreement”) with Mr. Marshall Faulk (“Faulk”). Pursuant to the Settlement Agreement, Faulk agreed to assign a promissory note issued by the Company to Faulk on December 10, 2015 in the principal amount of $100,000.00 (the “Prior Note”), under which the Company was in default, to Mr. Robert J. Dailey (“Dailey”) pursuant to a Debt Purchase and Exchange Agreement (the “Exchange Agreement”) between the parties. In addition, Faulk agreed to waive all claims against the Company relating to the Prior Note. In consideration for the foregoing, the Company agreed to issue Faulk 2,000,000 restricted common shares.   On May 1, 2017, the Company issued a warrant to purchase 1,500,000 shares of the Company’s common stock, at an exercise price of $0.15 per share. The warrant expires on May 1, 2022.   As of May 12, 2017, the Company had outstanding 304,140,678 shares of common stock.

Basis of Presentation   The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2016 (including the notes thereto) set forth in Form 10-K.    The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2016. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Revenue Recognition   We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. This standard permits early adoption and permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the potential impact of this standard on our financial position and results of operations, as well as our selected transition method. Based on our preliminary assessment, we believe the new standard will not have a material impact on our financial position and results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions.

Leases   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.

Use of Estimates   The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2017, the Company has no cash balances in excess of insured limits.

Segment and Geographic Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.

Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Fair Value Measurements   The ASC Topic 820, Fair Value Measurement, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer’s creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.

Fixed Assets   Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the three months ended March 31, 2017 and March 31, 2016 was $144 and $547, respectively.

Intangible Assets   Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of ten to sixteen years. Intangible assets are stated at the lower of cost or estimated fair value. During the years ended December 31, 2016 and December 31, 2015, the Company capitalized $nil and $nil respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10). Amortization expense for the three months ended March 31, 2017 and March 31, 2016 was $0 and $0, respectively.

Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. In 2015, the Company determined that the carrying amount recorded for the acquisition of licenses and patents related to LDN were impaired, and recorded an impairment loss of $5,226,352. No such impairment charges were recorded in 2016 or the first quarter of 2017.

Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes   The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2017 and 2016, the Company does not have a liability for unrecognized tax uncertainties.   The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2017, and 2016, the Company has not accrued any interest or penalties related to uncertain tax positions.

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

Non-controlling Interest   In accordance with ASC Topic 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.

Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.   A calculation of basic net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(2,705,933</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(136,563</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,569,370</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstanding—Denominator for basic net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">259,291,541</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.01</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td></tr> </table>   The Company’s potential dilutive securities, which include warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.   The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Warrants to purchase Common stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,525,237</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

Recent Accounting Standards   During the quarter ended March 31, 2017, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. This standard permits early adoption and permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the potential impact of this standard on our financial position and results of operations, as well as our selected transition method. Based on our preliminary assessment, we believe the new standard will not have a material impact on our financial position and results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions.    In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Warrants to purchase Common stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,525,237</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fixed Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 115%">Computer equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">9,738</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">9,738</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(8,032</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(7,888</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">1,706</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">1,850</td> <td style="line-height: 115%"> </td></tr> </table>

Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Accrued payroll to officers and others</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">1,272,703</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">1,126,261</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Accrued interest and penalties - notes payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,412,535</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,902,018</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Estimated legal settlement</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">128,087</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">128,087</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">167,092</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">393</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total accrued expenses and other liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,980,417</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,156,759</td> <td style="line-height: 115%"> </td></tr> </table>

Notes payable consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%; text-align: justify; line-height: 115%">Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earns interest at a rate of 18% per annum.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 16%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at March 31, 2017, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">286,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">286,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and September 30, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $591,494 were in default at March 31, 2017, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">704,494</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">704,494</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">425,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">425,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,000</td> <td style="line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%; text-align: justify; line-height: 115%">Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended March 31, 2017.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 16%; text-align: right; line-height: 115%">554,882</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">112,737</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">112,737</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued in July 2016 with an original issuance discount of $30,000. Net proceeds were $150,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">180,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">180,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,641.88. The note was in default on March 31, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">95,061</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">120,987</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on September 30, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Notes aggregating $1,354,000 were issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,354,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,354,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Notes aggregating $500,000 were issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued February 28, 2017, originally for $675,000, convertible into common stock of the Company in accordance with the conversion provisions of the note. In March 2017, $112,700 of the note was converted into 5 million common shares of the Company.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562,300</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Original issue discounts on notes payable and warrants issued with notes.</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(33,333</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(18,681</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,742,259</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,225,419</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Current Portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,742,259</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,225,419</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Long-Term debt, less current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

6. Capital Structure—Common Stock and Common Stock Purchase Warrants   Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.   As of March 31, 2017 and 2016, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.   As of March 31, 2017, the Company had 275,640,678 shares of common stock outstanding, and 250,428,133 outstanding as of December 31, 2016.   Stock Warrants   In the quarter ended March 31, 2017, there were no new warrants issued by the Company.   There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2017 and 2016.   Following is a summary of outstanding stock warrants at March 31, 2017 and activity during the three months then ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Warrants as of December 31, 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">59,191,904</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$ </td> <td style="width: 13%; text-align: right; line-height: 115%">0.03-15.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">0.35</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Issued in 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expired and forfeited</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,010,220</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,656,447</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,525,237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"> 0.03-15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.39</td> <td style="line-height: 115%"> </td></tr> </table>   Summary of outstanding warrants as of March 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Expiration Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Remaining Life (years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Fourth Quarter 2017</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">350,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">1.50-9.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">0.50</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">127,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,089,166</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,024,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">135,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07-0.23</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">260,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">300,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,000,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,806,237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03-0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,150,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.15-0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.25</td> <td style="line-height: 115%"> </td></tr> </table>

Following is a summary of outstanding stock warrants at March 31, 2017 and activity during the three months then ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Warrants as of December 31, 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">59,191,904</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$ </td> <td style="width: 13%; text-align: right; line-height: 115%">0.03-15.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">0.35</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Issued in 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expired and forfeited</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,010,220</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,656,447</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">0.03</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of March 31, 2017</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">52,525,237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"> 0.03-15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.39</td> <td style="line-height: 115%"> </td></tr> </table>

Summary of outstanding warrants as of March 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Expiration Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Remaining Life (years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Fourth Quarter 2017</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">350,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">1.50-9.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">0.50</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">127,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,089,166</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,024,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">135,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.07-0.23</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">260,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">300,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Fourth Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,000,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,806,237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.03-0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,150,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.15-0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.25</td> <td style="line-height: 115%"> </td></tr> </table>

10. Commitments and Contingencies   Malawi Treatment Facilities   On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases.    In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct two trials involving Lodonal™ in Malawi:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 115%">a. </td> <td style="text-align: justify; line-height: 115%">The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The PMPB approved the trial in late 2016 and recruitment began in late 2016 and continued through first quarter of 2017, with the trial now ongoing. </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">b. </td> <td style="text-align: justify; line-height: 115%">The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The Company has put this trial on hold as it may not be necessary with the approval in Nigeria in addition to the pending approval in Kenya and Senegal for Lodonal™ for the treatment of cancer.</td></tr> </table>   Distribution Agreements in Nigeria   Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria.   The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted.   In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The agreement expires in December 2018. The Company expects to implement the agreement in 2017, upon receipt of approvals from NAFDAC for the sale of LodonalTM in Nigeria. Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.   In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote LodonalTM upon execution of a definitive agreement between the companies and receipt of NAFDAC and other approvals to distribute LodonalTM in Nigeria.   Agreements with Hubei Qianjiang Pharmaceutical Company   On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account.   On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following:   Exploratory Toxicology (nGLP)   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Dose range finding studies</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Different species and methods of administration</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Multiple dosing regimens</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Estimate the response vs. dose given</td></tr> </table>   Definitive Toxicology (GLP)   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">General toxicology studies</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Different species and methods of administration</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Immunogenicity study with NHPs</td></tr> </table>   Special Toxicology Studies (planned)   Pursuant to the Amendment, Qianjiang Pharmaceutical has made certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States in 2016. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China.   In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein.   In December of 2016 Qianjiang Pharmaceutical completed the following documents:   Exploratory Toxicology (nGLP)   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Dose range finding studies</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Different species and methods of administration</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Multiple dosing regimens</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">●</td> <td style="line-height: 115%">Estimate the response vs. dose given</td></tr> </table>   Definitive Toxicology (GLP)   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">General toxicology studies</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">● </td> <td style="text-align: justify; line-height: 115%">Different species and methods of administration</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">● </td> <td style="line-height: 115%">Immunogenicity study with NHPs</td></tr> </table>   In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK.   Contract Manufacturing Agreements   On May 16, 2016, the Company entered into an agreement with Complete Pharmacy and Medical Solutions, LLC (“CPMS”) to compound, package and distribute the LDN tablets, capsules and/or creams in the United States. The initial term of the agreement is three years, with the option to renew for an additional year. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach, provided however that if the Company terminates the agreement, the Company will be required to reimburse CPMS for all unused packaging materials for the LDN, which unused packaging materials CPMS will provide to IMUN. If CPMS does not receive and ship at least 1,000 orders (prescriptions) during the term of the agreement, the Company will be required to reimburse CPMS for 100% of the “ramp up costs” (defined as all costs and expenses of labor and materials related to the testing, and required FDA and other governmental documentation/approvals of test data) of providing and producing the LDN, even where the Company cancels/terminates the agreement, which provision shall survive the cancellation/termination of the agreement.   On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”) entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms.   In January of 2017, Acromax obtained from the Ministry of Public Health and Social Assistance a Medications and Specialized Pharmaceuticals Registration Certification for LodonalTM, which allows for the manufacture and sale of LodonalTM in the Dominican Republic and for export. The Ministry also issued a Certificate of Pharmaceutical Product for Nigeria, Kenya, Senegal and Malawi, which will allow for the export of LodonalTM to those countries where we have drug and marketing approval.   Operating Leases   At March 31, 2017, the Company was a party to an agreement to lease office space in Orlando, Florida. Rent expense for the quarters ended March 31, 2017 and 2016 was $4,129 and $(114,794), respectively. The 2016 expense reflects the reversal of accruals for rent expense in prior years, including the settlement with E.J. Krause & Associates, Inc.   Legal Proceedings   None.

EX-101.SCH 5 imun-20170331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes - Results of Operations link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Licenses and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Organization and Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Fixed Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Income Taxes - Results of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Licenses and Supply Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 imun-20170331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 imun-20170331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 imun-20170331_lab.xml XBRL LABEL FILE Legal Entity [Axis] Cytocom Inc., [Member] Debt Instrument [Axis] Notes Payable One [Member] Notes Payable Two [Member] Notes Payable Three [Member] Notes Payable Four [Member] Notes Payable Five [Member] Notes Payable Six [Member] Notes Payable Seven [Member] Notes Payable Eight [Member] Related Party [Axis] Ira Gaines [Member] Lenders [Member] Award Date [Axis] May 1, 2015 [Member] Range [Axis] Minimum [Member] Maximum [Member] Lenders [Member] April 29, 2015 [Member] Lender [Member] Equity Components [Axis] Warrant [Member] Class of Warrant or Right [Axis] Fourth Quarter 2020 [Member] Fourth Quarter 2017 [Member] First Quarter 2018 [Member] Second Quarter 2018 [Member] Third Quarter 2018 [Member] Fourth Quarter 2018 [Member] First Quarter 2019 [Member] Second Quarter 2019 [Member] Third Quarter 2019 [Member] Fourth Quarter 2019 [Member] Second Quarter 2020 [Member] Agreement [Axis] Young Agreement [Member] Dr. Bernard Bihari [Member] Smith Agreement [Member] Scenario [Axis] Initial License Fee [Member] Expenses [Member] Shan Agreement [Member] Agreements With Hubei Qianjiang Pharmaceutical Company [Member] Common Stock [Member] Additional Paid-In Capital [Member] Stock to Be Issued [Member] Accumulated Deficit [Member] Non-Controlling Interest [Member] Notes Payable Nine [Member] Notes Payable Ten [Member] First Quarter 2021 [Member] Notes Payable Eleven [Member] Complete Pharmacy and Medical Solutions, LLC [Member] Notes Payable Twelve [Member] Notes Payable Thirteen [Member] Notes Payable Fourteen [Member] Notes Payable Fifteen [Member] Title of Individual [Axis] Second Quarter 2021 [Member] Third Quarter 2021 [Member] Dr. Plotnikoff [Member] TNI IP's Management [Member] TNI BioTech IP, Inc. [Member] AHAR Pharma [Member] Prepaid Services [Member] Irish Limited Liability [Member] Report Date [Axis] December 31, 2017 [Member] Property, Plant and Equipment, Type [Axis] Property and Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intangible Assets [Member] March 31, 2018 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Consulting Fees [Member] Debt Conversion [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] Mr. Marshall Faulk [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Total current assets Fixed Assets: Computer equipment, net of accumulated depreciation of $8,032 and $7,888 respectively Deposits Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable Accrued liabilities Current portion of notes payable, net of debt discount Total current liabilities Total liabilities Commitments and Contingencies (Note 10) Stockholders' Deficit: Common stock - par value $0.0001; 500,000,000 shares authorized; 275,640,678 and 250,428,133 shares issued and outstanding respectively Additional paid in capital Stock issuances due Prepaid services Accumulated deficit Deficit attributable to common stockholders Non-controlling interest Total stockholders' deficit Total liabilities and stockholders' deficit Accumulated depreciation Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Operating expenses: Selling, general and administrative Research and development expense Stock issued for services G&A Warrant valuation expense Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense): Interest expense Loss on settlement of debt Total other income (expense) Net loss Net loss attributable to non-controlling interest Net loss attributable to common shareholders Basic loss per share to common shareholders Weighted average number of shares outstanding Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock for prepaid services Issuance of common stock for prepaid services, shares Amortization of prepaid services Issuance of common stock in exchange for debt Issuance of common stock in exchange for debt, shares Issuance of common stock for exercise of warrants Issuance of common stock for exercise of warrants, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash flows used in operating activities: Depreciation Amortization of debt discount Amortization of stock issued for prepaid services Stock issued for services Stock warrant expense Loss on settlement of debt Changes in operating assets and liabilities: Accounts receivable Accounts payable Accrued liabilities Prepaid expenses and other current assets Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of stock and exercise of warrants Payment of notes payable Proceeds from issuance of notes payable Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Debt discount Shares issued for debt and accrued interest Shares issued for accounts payable and accrued expenses Cashless exercise of warrants Estimated loss on debt conversion Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Description of Business EX-101.PRE 9 imun-20170331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 12, 2017
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	0001559356
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		304,140,678
Trading Symbol	IMUN
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 98,113	$ 74,389
Total current assets	98,113	74,389
Fixed Assets:
Computer equipment, net of accumulated depreciation of $8,032 and $7,888 respectively	1,706	1,850
Deposits	200	200
Total assets	100,019	76,439
Current Liabilities:
Accounts payable	1,666,406	1,818,605
Accrued liabilities	3,980,417	3,156,759
Current portion of notes payable, net of debt discount	4,742,259	4,225,419
Total current liabilities	10,389,082	9,200,783
Total liabilities	10,389,082	9,200,783
Stockholders' Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 275,640,678 and 250,428,133 shares issued and outstanding respectively	27,564	25,043
Additional paid in capital	361,542,431	360,420,026
Stock issuances due	1,432,883	962,429
Prepaid services	(876,666)	(822,500)
Accumulated deficit	(368,288,346)	(365,718,976)
Deficit attributable to common stockholders	(6,162,134)	(5,133,978)
Non-controlling interest	(4,126,929)	(3,990,366)
Total stockholders' deficit	(10,289,063)	(9,124,344)
Total liabilities and stockholders' deficit	$ 100,019	$ 76,439

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 8,032	$ 7,888	$ 7,888
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	275,640,678	250,428,133
Common stock, shares outstanding	275,640,678	250,428,133

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues, net		$ 3,463
Operating expenses:
Selling, general and administrative	666,091	939,341
Research and development expense	118,656	(18,842)
Stock issued for services G&A	731,288	1,983,837
Warrant valuation expense		2,078,199
Depreciation and amortization expense	144	547
Total operating expenses	1,516,179	4,983,082
Loss from operations	(1,516,179)	(4,979,619)
Other income (expense):
Interest expense	(575,828)	(301,444)
Loss on settlement of debt	(613,926)	(1,364,339)
Total other income (expense)	(1,189,754)	(1,665,783)
Net loss	(2,705,933)	(6,645,402)
Net loss attributable to non-controlling interest	(136,563)	(44,120)
Net loss attributable to common shareholders	$ (2,569,370)	$ (6,601,282)
Basic loss per share to common shareholders	$ (0.01)	$ (0.03)
Weighted average number of shares outstanding	259,291,541	190,923,381

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock to Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2016	$ 25,043	$ 360,420,026	$ 962,429	$ (822,500)	$ (365,718,976)	$ (3,990,366)	$ (9,124,344)
Balance, shares at Dec. 31, 2016	250,428,133
Issuance of common stock for prepaid services	$ 605	314,396	470,454	(420,000)			$ 365,455
Issuance of common stock for prepaid services, shares	6,045,460						6,045,460
Amortization of prepaid services				365,834			$ 365,834
Issuance of common stock in exchange for debt	$ 1,751	808,174					809,925
Issuance of common stock in exchange for debt, shares	17,510,638
Issuance of common stock for exercise of warrants	$ 165	(165)
Issuance of common stock for exercise of warrants, shares	1,656,447
Net loss					(2,569,370)	(136,563)	(2,705,933)
Balance at Mar. 31, 2017	$ 27,564	$ 361,542,431	$ 1,432,883	$ (876,666)	$ (368,288,346)	$ (4,126,929)	$ (10,289,063)
Balance, shares at Mar. 31, 2017	275,640,678

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,705,933)	$ (6,645,402)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	144	547
Amortization of debt discount	35,346
Amortization of stock issued for prepaid services	365,834	669,667
Stock issued for services	365,455	1,314,169
Stock warrant expense		2,078,199
Loss on settlement of debt	613,926	1,364,339
Changes in operating assets and liabilities:
Accounts receivable		(3,463)
Accounts payable	138,840	139,203
Accrued liabilities	656,958	486,373
Prepaid expenses and other current assets		(1,594)
Net cash used in operating activities	(529,430)	(597,962)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants		50,000
Payment of notes payable	(321,846)
Proceeds from issuance of notes payable	875,000	657,000
Net cash provided by financing activities	553,154	707,000
Net decrease in cash and cash equivalents	23,724	109,038
Cash and cash equivalents at beginning of period	74,389	23,149
Cash and cash equivalents at end of period	98,113	132,817
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	13,000	7,050
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount	50,000
Shares issued for debt and accrued interest	362,700	2,306,415
Shares issued for accounts payable and accrued expenses	339,339
Cashless exercise of warrants	165
Estimated loss on debt conversion	$ 215,000

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

1. Organization and Description of Business

Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

Revenue Recognition

Leases

Use of Estimates

Cash, Cash Equivalents, and Short-Term Investments

Concentration of Credit Risk

Segment and Geographic Information

Fair Value of Financial Instruments

Fair Value Measurements

Fixed Assets

Intangible Assets

Impairment of Long-Lived Assets

Research and Development Costs

Income Taxes

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Non-controlling Interest

Net Loss per Share

A calculation of basic net loss per share follows:

	For the three months ended March 31,
	2017			2016
Historical net loss per share:
Numerator
Net loss	$	(2,705,933	)	$	(6,645,402	)
Non-controlling interest		(136,563	)		(44,120	)
Net loss attributed to Common stockholders	$	(2,569,370	)	$	(6,601,282	)

Denominator
Weighted-average common shares outstanding—Denominator for basic net loss per share		259,291,541			190,923,381
Basic net loss per share attributed to common stockholders	$	(0.01	)	$	(0.03	)

The Company’s potential dilutive securities, which include warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.

	For the three months ended March 31,
	2017		2016
Warrants to purchase Common stock		52,525,237		24,731,500

Recent Accounting Standards

XML 18 R9.htm IDEA: XBRL DOCUMENT

Fixed Assets

3 Months Ended

Mar. 31, 2017

Fixed Assets:

Fixed Assets

3. Fixed Assets

	March 31, 2017			December 31, 2016
Fixed Assets:
Computer equipment	$	9,738		$	9,738
Less accumulated depreciation		(8,032	)		(7,888	)
Property and equipment, net	$	1,706		$	1,850

The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

4. Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2017		December 31, 2016

Accrued payroll to officers and others	$	1,272,703	$	1,126,261
Accrued interest and penalties - notes payable		2,412,535		1,902,018
Estimated legal settlement		128,087		128,087
Other accrued liabilities		167,092		393

Total accrued expenses and other liabilities	$	3,980,417	$	3,156,759

XML 20 R11.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Notes Payable

5. Notes Payable

Notes payable consist of the following:

	March 31, 2017		December 31, 2016
Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earns interest at a rate of 18% per annum.	$	100,000	$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at March 31, 2017, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders.		286,000		286,000

Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and September 30, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $591,494 were in default at March 31, 2017, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders.		704,494		704,494

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.		425,000		425,000

Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.		100,000		100,000

Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended March 31, 2017.		-			554,882

Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default.		112,737			112,737

Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default.		50,000			50,000

Promissory note issued in July 2016 with an original issuance discount of $30,000. Net proceeds were $150,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default.		180,000			180,000

Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,641.88. The note was in default on March 31, 2017.		95,061			120,987

Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on September 30, 2017.		256,000			256,000

Notes aggregating $1,354,000 were issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017.		1,354,000			1,354,000

Notes aggregating $500,000 were issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018.		500,000			-

Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017.		50,000			-

Promissory note issued February 28, 2017, originally for $675,000, convertible into common stock of the Company in accordance with the conversion provisions of the note. In March 2017, $112,700 of the note was converted into 5 million common shares of the Company.		562,300			-

Less: Original issue discounts on notes payable and warrants issued with notes.		(33,333	)		(18,681	)

Total		4,742,259			4,225,419

Less: Current Portion	$	(4,742,259	)	$	(4,225,419	)

Long-Term debt, less current portion	$	-		$	-

XML 21 R12.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Capital Structure - Common Stock and Common Stock Purchase Warrants

6. Capital Structure—Common Stock and Common Stock Purchase Warrants

As of March 31, 2017 and 2016, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.

As of March 31, 2017, the Company had 275,640,678 shares of common stock outstanding, and 250,428,133 outstanding as of December 31, 2016.

Stock Warrants

In the quarter ended March 31, 2017, there were no new warrants issued by the Company.

There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2017 and 2016.

Following is a summary of outstanding stock warrants at March 31, 2017 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2016		59,191,904	$	0.03-15.00	$	0.35

Issued in 2017		-	$	-	$	-

Expired and forfeited		5,010,220	$	0.03	$	0.03

Exercised		1,656,447	$	0.03	$	0.03

Warrants as of March 31, 2017		52,525,237	$	0.03-15.00	$	0.39

Summary of outstanding warrants as of March 31, 2017:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)

Fourth Quarter 2017		350,000	$	1.50-9.00		0.50
First Quarter 2018		127,500	$	15.00		0.75
Second Quarter 2018		33,334	$	15.00		1.00
Third Quarter 2018		250,000	$	1.50		1.25
Fourth Quarter 2018		6,089,166	$	1.00-1.50		1.50
First Quarter 2019		4,024,000	$	0.50-2.00		1.75
Second Quarter 2019		135,000	$	0.07-0.23		2.00
Third Quarter 2019		260,000	$	0.50-1.50		2.25
Fourth Quarter 2019		400,000	$	0.14		2.50
Second Quarter 2020		300,000	$	0.50		3.00
Fourth Quarter 2020		1,000,000	$	0.20		3.50
First Quarter 2021		12,600,000	$	0.20		3.75
Second Quarter 2021		23,806,237	$	0.03-0.20		4.00
Third Quarter 2021		3,150,000	$	0.15-0.20		4.25

XML 22 R13.htm IDEA: XBRL DOCUMENT

Stock Compensation

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Compensation

7. Stock Compensation

Shares Issued for Services

XML 23 R14.htm IDEA: XBRL DOCUMENT

Income Taxes - Results of Operations

3 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes - Results of Operations

8. Income Taxes - Results of Operations

There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2017 and 2016 because the Company incurred a net loss in both quarters.

As of December 31, 2016, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $79,900,000, which will expire in 2032-2035.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Licenses and Supply Agreements

3 Months Ended

Mar. 31, 2017

Licenses And Supply Agreements

Licenses and Supply Agreements

9. Licenses and Supply Agreements

Patent and Subsidiary Acquisition

Patent License Agreements

XML 25 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

Malawi Treatment Facilities

a.	The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The PMPB approved the trial in late 2016 and recruitment began in late 2016 and continued through first quarter of 2017, with the trial now ongoing.

b.	The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The Company has put this trial on hold as it may not be necessary with the approval in Nigeria in addition to the pending approval in Kenya and Senegal for Lodonal™ for the treatment of cancer.

Distribution Agreements in Nigeria

Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria.

The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted.

Agreements with Hubei Qianjiang Pharmaceutical Company

Exploratory Toxicology (nGLP)

	●	Dose range finding studies
	●	Different species and methods of administration
	●	Multiple dosing regimens
	●	Estimate the response vs. dose given

Definitive Toxicology (GLP)

	●	Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)
	●	General toxicology studies
	●	Different species and methods of administration
	●	Immunogenicity study with NHPs

Special Toxicology Studies (planned)

In December of 2016 Qianjiang Pharmaceutical completed the following documents:

Exploratory Toxicology (nGLP)

	●	Dose range finding studies
	●	Different species and methods of administration
	●	Multiple dosing regimens
	●	Estimate the response vs. dose given

Definitive Toxicology (GLP)

	●	Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)
	●	General toxicology studies
	●	Different species and methods of administration
	●	Immunogenicity study with NHPs

In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK.

Contract Manufacturing Agreements

Operating Leases

Legal Proceedings

None.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

On May 1, 2017, the Company issued a warrant to purchase 1,500,000 shares of the Company’s common stock, at an exercise price of $0.15 per share. The warrant expires on May 1, 2022.

As of May 12, 2017, the Company had outstanding 304,140,678 shares of common stock.

XML 27 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Revenue Recognition

Revenue Recognition

Leases

Leases

Use of Estimates

Use of Estimates

Cash, Cash Equivalents, and Short-term Investments

Cash, Cash Equivalents, and Short-Term Investments

Concentration of Credit Risk

Concentration of Credit Risk

Segment and Geographic Information

Segment and Geographic Information

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Measurements

Fair Value Measurements

Fixed Assets

Fixed Assets

Intangible Assets

Intangible Assets

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Research and Development Costs

Research and Development Costs

Income Taxes

Income Taxes

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Non-controlling Interest

Non-controlling Interest

Net Loss Per Share

Net Loss per Share

A calculation of basic net loss per share follows:

	For the three months ended March 31,
	2017			2016
Historical net loss per share:
Numerator
Net loss	$	(2,705,933	)	$	(6,645,402	)
Non-controlling interest		(136,563	)		(44,120	)
Net loss attributed to Common stockholders	$	(2,569,370	)	$	(6,601,282	)

Denominator
Weighted-average common shares outstanding—Denominator for basic net loss per share		259,291,541			190,923,381
Basic net loss per share attributed to common stockholders	$	(0.01	)	$	(0.03	)

The Company’s potential dilutive securities, which include warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.

	For the three months ended March 31,
	2017		2016
Warrants to purchase Common stock		52,525,237		24,731,500

Recent Accounting Standards

Recent Accounting Standards

XML 28 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

A calculation of basic net loss per share follows:

	For the three months ended March 31,
	2017			2016
Historical net loss per share:
Numerator
Net loss	$	(2,705,933	)	$	(6,645,402	)
Non-controlling interest		(136,563	)		(44,120	)
Net loss attributed to Common stockholders	$	(2,569,370	)	$	(6,601,282	)

Denominator
Weighted-average common shares outstanding—Denominator for basic net loss per share		259,291,541			190,923,381
Basic net loss per share attributed to common stockholders	$	(0.01	)	$	(0.03	)

Schedule of Antidilutive Securities

	For the three months ended March 31,
	2017		2016
Warrants to purchase Common stock		52,525,237		24,731,500

XML 29 R20.htm IDEA: XBRL DOCUMENT

Fixed Assets (Tables)

3 Months Ended

Mar. 31, 2017

Fixed Assets:

Schedule of Fixed Assets

	March 31, 2017			December 31, 2016
Fixed Assets:
Computer equipment	$	9,738		$	9,738
Less accumulated depreciation		(8,032	)		(7,888	)
Property and equipment, net	$	1,706		$	1,850

XML 30 R21.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2017		December 31, 2016

Accrued payroll to officers and others	$	1,272,703	$	1,126,261
Accrued interest and penalties - notes payable		2,412,535		1,902,018
Estimated legal settlement		128,087		128,087
Other accrued liabilities		167,092		393

Total accrued expenses and other liabilities	$	3,980,417	$	3,156,759

XML 31 R22.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following:

	March 31, 2017		December 31, 2016
Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. The note earns interest at a rate of 18% per annum.	$	100,000	$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at March 31, 2017, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders.		286,000		286,000

Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and September 30, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $591,494 were in default at March 31, 2017, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders.		704,494		704,494

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. At March 31, 2017, the notes were in default, although no demand for repayment has been made by the lenders.		425,000		425,000

Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. At March 31, 2017, the note was in default, although no demand for repayment has been made by the lender. On April 3, 2017, the Company settled the obligation.		100,000		100,000

Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended March 31, 2017.		-			554,882

Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default.		112,737			112,737

Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default.		50,000			50,000

Promissory note issued in July 2016 with an original issuance discount of $30,000. Net proceeds were $150,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default.		180,000			180,000

Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,641.88. The note was in default on March 31, 2017.		95,061			120,987

Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on September 30, 2017.		256,000			256,000

Notes aggregating $1,354,000 were issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017.		1,354,000			1,354,000

Notes aggregating $500,000 were issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018.		500,000			-

Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017.		50,000			-

Promissory note issued February 28, 2017, originally for $675,000, convertible into common stock of the Company in accordance with the conversion provisions of the note. In March 2017, $112,700 of the note was converted into 5 million common shares of the Company.		562,300			-

Less: Original issue discounts on notes payable and warrants issued with notes.		(33,333	)		(18,681	)

Total		4,742,259			4,225,419

Less: Current Portion	$	(4,742,259	)	$	(4,225,419	)

Long-Term debt, less current portion	$	-		$	-

XML 32 R23.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Schedule of Outstanding Stock Warrants

Following is a summary of outstanding stock warrants at March 31, 2017 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2016		59,191,904	$	0.03-15.00	$	0.35

Issued in 2017		-	$	-	$	-

Expired and forfeited		5,010,220	$	0.03	$	0.03

Exercised		1,656,447	$	0.03	$	0.03

Warrants as of March 31, 2017		52,525,237	$	0.03-15.00	$	0.39

Summary of Outstanding Warrants

Summary of outstanding warrants as of March 31, 2017:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)

Fourth Quarter 2017		350,000	$	1.50-9.00		0.50
First Quarter 2018		127,500	$	15.00		0.75
Second Quarter 2018		33,334	$	15.00		1.00
Third Quarter 2018		250,000	$	1.50		1.25
Fourth Quarter 2018		6,089,166	$	1.00-1.50		1.50
First Quarter 2019		4,024,000	$	0.50-2.00		1.75
Second Quarter 2019		135,000	$	0.07-0.23		2.00
Third Quarter 2019		260,000	$	0.50-1.50		2.25
Fourth Quarter 2019		400,000	$	0.14		2.50
Second Quarter 2020		300,000	$	0.50		3.00
Fourth Quarter 2020		1,000,000	$	0.20		3.50
First Quarter 2021		12,600,000	$	0.20		3.75
Second Quarter 2021		23,806,237	$	0.03-0.20		4.00
Third Quarter 2021		3,150,000	$	0.15-0.20		4.25

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

Organization and Description of Business (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 08, 2014	Apr. 30, 2016	Mar. 31, 2014	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2013	Dec. 31, 2016
Net loss				$ 2,705,933	$ 6,645,402
Cash equivalents				529,430
Stockholders equity				$ 10,289,063			$ 9,124,344
Cytocom Inc., [Member]
Number of shares issued during period	113,242,522					140,100,000
Percentage of stake issued during period				13.30%		55.30%
Reserve stock split description		the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock.
Irish Limited Liability [Member]
Percentage of low corporate income tax rate			12.50%

XML 34 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) Segment	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Maximum of annual gross revenue			$ 1,000,000,000
Federal deposit insurance corporation value	$ 250,000
Number of operating segment \| Segment	1
Depreciation expense	$ 144	$ 547
Intangible assets cost capitalized and amortized
Amortization expense	0	$ 0
Impairment loss				$ 5,226,352
Accrued interest or penalties related to uncertain tax positions
Minimum [Member]
Property and equipment useful lives	3 years
Minimum [Member] \| Intangible Assets [Member]
Intangible assets useful lives	10 years
Maximum [Member]
Property and equipment useful lives	5 years
Maximum [Member] \| Intangible Assets [Member]
Intangible assets useful lives	16 years
Property and Equipment [Member] \| Minimum [Member]
Property and equipment useful lives	3 years
Property and Equipment [Member] \| Maximum [Member]
Property and equipment useful lives	5 years

XML 35 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Numerator, Net loss	$ (2,705,933)	$ (6,645,402)
Numerator, Non-controlling interest	(136,563)	(44,120)
Numerator, Net loss attributed to Common stockholders	$ (2,569,370)	$ (6,601,282)
Denominator, Weighted-average common shares outstanding-Denominator for basic net loss per share	259,291,541	190,923,381
Denominator, Basic net loss per share attributed to common stockholders	$ (0.01)	$ (0.03)

XML 36 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Potentially dilutive securities	52,525,237	24,731,500

XML 37 R28.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details Narrative)	3 Months Ended
Fixed Assets (Details Narrative)	Mar. 31, 2017
Minimum [Member]
Depreciable asset lives	3 years
Maximum [Member]
Depreciable asset lives	5 years

XML 38 R29.htm IDEA: XBRL DOCUMENT

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Fixed Assets:
Computer equipment	$ 9,738		$ 9,738
Less accumulated depreciation	(8,032)	$ (7,888)	(7,888)
Property and equipment, net	$ 1,706	$ 1,850	$ 1,850

XML 39 R30.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued payroll to officers and others	$ 1,272,703	$ 1,126,261
Accrued interest and penalties - notes payable	2,412,535	1,902,018
Estimated legal settlement	128,087	128,087
Other accrued liabilities	167,092	393
Total accrued expenses and other liabilities	$ 3,980,417	$ 3,156,759

XML 40 R31.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative)	3 Months Ended
Notes Payable (Details Narrative)	Mar. 31, 2017 USD ($) shares
Debt Disclosure [Abstract]
Accrued unpaid interest	$ 2,412,535
Issuance of common stock for interest expense, shares \| shares	17,510,638
Issuance of common stock for interest expense	$ 809,925

XML 41 R32.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Jul. 31, 2016
Total	$ 4,742,259	$ 4,225,419
Less: Original issue discounts on notes payable and warrants issued with notes	(33,333)	(18,681)	$ 30,000
Less: Current portion	(4,742,259)	(4,225,419)
Long-Term debt, less current portion
Notes Payable One [Member]
Total	100,000	100,000
Notes Payable Two [Member]
Total	286,000	286,000
Notes Payable Three [Member]
Total	704,494	704,494
Notes Payable Four [Member]
Total	425,000	425,000
Notes Payable Five [Member]
Total	100,000	100,000
Notes Payable Six [Member]
Total		554,882
Notes Payable Seven [Member]
Total	112,737	112,737
Notes Payable Eight [Member]
Total	50,000	50,000
Notes Payable Nine [Member]
Total	180,000	180,000
Notes Payable Ten [Member]
Total	95,061	120,987
Notes Payable Eleven [Member]
Total	256,000	256,000
Notes Payable Twelve [Member]
Total	1,354,000	1,354,000
Notes Payable Thirteen [Member]
Total	500,000
Notes Payable Fourteen [Member]
Total	50,000
Notes Payable Fifteen [Member]
Total	$ 562,300

XML 42 R33.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)								3 Months Ended		12 Months Ended
	Feb. 28, 2017 USD ($)	Jan. 25, 2017	Aug. 31, 2016 USD ($) Installments	Jul. 31, 2016 USD ($)	Jun. 02, 2016	Nov. 03, 2015	Jul. 29, 2014	Mar. 31, 2017 USD ($) Doses shares	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015	Sep. 30, 2015 USD ($)
Note matures date				Apr. 07, 2017		Nov. 03, 2016
Percentage of interest rate per annum			5.00%	6.00%		10.00%						10.00%
Maximum amount raise in debt			$ 149,854									$ 2,000,000
Number of installments, months			18					36
Debt instrument maturity date description					October 1, 2016 and January 31, 2017
Original issuance discount				$ 30,000				$ (33,333)		$ (18,681)
Proceeds from issuance of debt				$ 150,000				875,000	$ 657,000
Debt instrument, periodic payment, principal			$ 8,642
Number of shares converted amount	$ 675,000							$ 112,700
Number of shares converted \| shares								5,000,000
December 31, 2017 [Member]
Percentage of interest rate per annum										2.00%
Notes aggregating default amount										$ 1,354,000
Debt instrument maturity date description										November 1, 2017 and December 31, 2017
March 31, 2018 [Member]
Percentage of interest rate per annum								2.00%
Notes aggregating default amount								$ 500,000
Debt instrument maturity date description								January 12, 2018 and March 31, 2018
Lenders [Member]
Note matures date										Sep. 30, 2017
Percentage of interest rate per annum										2.00%
Debt instrument maturity date description										between July 1, 2016 and December 31, 2016
April 29, 2015 [Member] \| Cytocom Inc., [Member]
Note matures date											Sep. 30, 2016
April 29, 2015 [Member] \| Minimum [Member] \| Cytocom Inc., [Member]
Percentage of interest rate per annum											5.00%
April 29, 2015 [Member] \| Maximum [Member] \| Cytocom Inc., [Member]
Percentage of interest rate per annum											10.00%
Ira Gaines [Member]
Note matures date							Dec. 01, 2017
Percentage of interest rate per annum							18.00%
Lenders [Member]
Note matures date		Jul. 05, 2017
Percentage of interest rate per annum		7.00%
Notes aggregating default amount								$ 286,000
Lenders [Member] \| Minimum [Member]
Percentage of interest rate per annum										2.00%
Lenders [Member] \| Maximum [Member]
Percentage of interest rate per annum										18.00%
Lenders [Member] \| May 1, 2015 [Member]
Note matures date										Sep. 30, 2017
Notes aggregating default amount										$ 591,494
Aggregating loan										505,994
Accrued interest										$ 198,500
Lenders [Member]
Notes aggregating default amount								$ 100,000
Lender [Member]
Percentage of interest rate per annum											10.00%

XML 43 R34.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	275,640,678	250,428,133
Common stock, shares outstanding	275,640,678	250,428,133
Number of warrants issued during period

XML 44 R35.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Warrants, Number of shares Beginning balance \| shares	59,191,904
Warrants, Number of shares Issued \| shares
Warrants, Number of shares Expired and forfeited \| shares	5,010,220
Warrants, Number of shares Exercised \| shares	1,656,447
Warrants, Number of shares Ending balance \| shares	52,525,237
Exercise Price, Issued
Exercise Price, Expired and forfeited	0.03
Exercise Price, Exercised	0.03
Weighted average exercise price, Beginning balance	0.35
Weighted average exercise price, Issued
Weighted average exercise price, Expired and forfeited	0.03
Weighted average exercise price, Exercised	0.03
Weighted average exercise price, Ending balance	0.39
Minimum [Member]
Exercise Price, Beginning balance	0.03
Exercise Price, Issued
Exercise Price, Ending balance	0.03
Maximum [Member]
Exercise Price, Beginning balance	15.00
Exercise Price, Issued
Exercise Price, Ending balance	$ 15.00

XML 45 R36.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Fourth Quarter 2017 [Member]
Number of Shares \| shares	350,000
Exercise Price Lower Limit	$ 1.50
Exercise Price Upper Limit	$ 9.00
Remaining Life (years)	6 months
First Quarter 2018 [Member]
Number of Shares \| shares	127,500
Exercise Price Upper Limit	$ 15.00
Remaining Life (years)	9 months
Second Quarter 2018 [Member]
Number of Shares \| shares	33,334
Exercise Price Upper Limit	$ 15.00
Remaining Life (years)	1 year
Third Quarter 2018 [Member]
Number of Shares \| shares	250,000
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	1 year 3 months
Fourth Quarter 2018 [Member]
Number of Shares \| shares	6,089,166
Exercise Price Lower Limit	$ 1.00
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	1 year 6 months
First Quarter 2019 [Member]
Number of Shares \| shares	4,024,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 2.00
Remaining Life (years)	1 year 9 months
Second Quarter 2019 [Member]
Number of Shares \| shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	2 years
Third Quarter 2019 [Member]
Number of Shares \| shares	260,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 years 3 months
Fourth Quarter 2019 [Member]
Number of Shares \| shares	400,000
Exercise Price Upper Limit	$ 0.14
Remaining Life (years)	2 years 6 months
Second Quarter 2020 [Member]
Number of Shares \| shares	300,000
Exercise Price Upper Limit	$ 0.50
Remaining Life (years)	3 years
Fourth Quarter 2020 [Member]
Number of Shares \| shares	1,000,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years 6 months
First Quarter 2021 [Member]
Number of Shares \| shares	12,600,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years 9 months
Second Quarter 2021 [Member]
Number of Shares \| shares	23,806,237
Exercise Price Lower Limit	$ 0.03
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	4 years
Third Quarter 2021 [Member]
Number of Shares \| shares	3,150,000
Exercise Price Lower Limit	$ 0.15
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	4 years 3 months

XML 46 R37.htm IDEA: XBRL DOCUMENT

Stock Compensation (Details Narrative) - USD ($)	3 Months Ended
Stock Compensation (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Number of common stock issued for consulting fees	6,045,460	19,043,000
Number of common stock issued for consulting fees, value	$ 365,455	$ 1,314,169
Amortization of prepaid services	$ 365,834	$ 669,667
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months

XML 47 R38.htm IDEA: XBRL DOCUMENT

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%	0.00%
Operating loss carryforwards	$ 79,900,000
Operating loss carryforwards expire term	expire in 2032-2035.

XML 48 R39.htm IDEA: XBRL DOCUMENT

Licenses and Supply Agreements (Details Narrative) - USD ($)						1 Months Ended	12 Months Ended
	Sep. 24, 2014	Aug. 06, 2014	Dec. 24, 2012	Aug. 13, 2012	Apr. 24, 2012	May 31, 2013	Dec. 31, 2013
Young Agreement [Member]
Patent liability							$ 118,333
Cost of patent							$ 1,372,000
Percentage of royalty payment							1.00%
Smith Agreement [Member]
Number of shares acquired in exchange for common stock	1,000,000		300,000
Acquisition value	$ 270,000		$ 2,880,384
Fair market value acquired			2,715,000
Payments to acquire patents			165,384
Smith Agreement [Member] \| Initial License Fee [Member]
Payments to acquire patents			100,000
Smith Agreement [Member] \| Expenses [Member]
Payments to acquire patents			$ 65,384
Shan Agreement [Member]
Number of shares issue upon final transfer of licenses						500,000
Number of common stock shares issued during period		500,000
TNI BioTech IP, Inc. [Member]
Number of shares acquired in exchange for common stock					20,250,000
Acquisition value					$ 98,000,000
Dr. Plotnikoff [Member]
Number of shares acquired in exchange for common stock					8,000,000
TNI IP's Management [Member]
Number of shares acquired in exchange for common stock					12,250,000
Acquisition value					$ 16,006,000
Dr. Bernard Bihari [Member] \| Young Agreement [Member]
Number of shares acquired in exchange for common stock				540,000
Acquisition value				$ 972,000
Assumed liabilities				$ 400,000

XML 49 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Oct. 18, 2012	Oct. 31, 2013	Mar. 31, 2017	Mar. 31, 2016
Cash rental expense				$ (114,794)
AHAR Pharma [Member]
Distribution agreement, description		the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.
Agreements With Hubei Qianjiang Pharmaceutical Company [Member]
Percentage of gross sales	6.00%
Complete Pharmacy and Medical Solutions, LLC [Member]
Ramp up costs, percentage			100.00%

XML 50 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)					3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	May 12, 2017	May 12, 2017	May 01, 2017	Apr. 04, 2017	Mar. 31, 2017	Dec. 31, 2016	Aug. 31, 2016	Sep. 30, 2015
Number of shares for debt conversion and settlements					17,510,638
Debt principal amount							$ 149,854	$ 2,000,000
Common stock, shares outstanding					275,640,678	250,428,133
Subsequent Event [Member]
Number of common stock issued	28,500,000
Number of shares sold for cash	10,000,000
Warrant to purchase of common stock			1,500,000
Warrant exercise price			$ 0.15
Warrant expire term			expires on May 1, 2022
Common stock, shares outstanding	304,140,678	304,140,678
Subsequent Event [Member] \| Settlement Agreement [Member] \| Mr. Marshall Faulk [Member]
Debt principal amount				$ 100,000
Number of restricted common stock				2,000,000
Subsequent Event [Member] \| Debt Conversion [Member]
Number of shares for debt conversion and settlements		5,500,000
Subsequent Event [Member] \| Consulting Fees [Member]
Number of common stock issued	13,000,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 158 197 1 false 68 0 false 7 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://immunetherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://immunetherapeutics.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://immunetherapeutics.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Fixed Assets Sheet http://immunetherapeutics.com/role/FixedAssets Fixed Assets Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Liabilities Sheet http://immunetherapeutics.com/role/AccruedLiabilities Accrued Liabilities Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://immunetherapeutics.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants Capital Structure - Common Stock and Common Stock Purchase Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Stock Compensation Sheet http://immunetherapeutics.com/role/StockCompensation Stock Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes - Results of Operations Sheet http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperations Income Taxes - Results of Operations Notes 14 false false R15.htm 00000015 - Disclosure - Licenses and Supply Agreements Sheet http://immunetherapeutics.com/role/LicensesAndSupplyAgreements Licenses and Supply Agreements Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://immunetherapeutics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://immunetherapeutics.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Fixed Assets (Tables) Sheet http://immunetherapeutics.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://immunetherapeutics.com/role/FixedAssets 20 false false R21.htm 00000021 - Disclosure - Accrued Liabilities (Tables) Sheet http://immunetherapeutics.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://immunetherapeutics.com/role/AccruedLiabilities 21 false false R22.htm 00000022 - Disclosure - Notes Payable (Tables) Notes http://immunetherapeutics.com/role/NotesPayableTables Notes Payable (Tables) Tables http://immunetherapeutics.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsTables Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) Tables http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants 23 false false R24.htm 00000024 - Disclosure - Organization and Description of Business (Details Narrative) Sheet http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative Organization and Description of Business (Details Narrative) Details http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusiness 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedNetLossPerShareDetails Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) Details 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) Details 27 false false R28.htm 00000028 - Disclosure - Fixed Assets (Details Narrative) Sheet http://immunetherapeutics.com/role/FixedAssetsDetailsNarrative Fixed Assets (Details Narrative) Details http://immunetherapeutics.com/role/FixedAssetsTables 28 false false R29.htm 00000029 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) Sheet http://immunetherapeutics.com/role/FixedAssets-ScheduleOfFixedAssetsDetails Fixed Assets - Schedule of Fixed Assets (Details) Details 29 false false R30.htm 00000030 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://immunetherapeutics.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Details Narrative) Notes http://immunetherapeutics.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://immunetherapeutics.com/role/NotesPayableTables 31 false false R32.htm 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://immunetherapeutics.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 32 false false R33.htm 00000033 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://immunetherapeutics.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 33 false false R34.htm 00000034 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) Details http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsTables 34 false false R35.htm 00000035 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants-ScheduleOfOutstandingStockWarrantsDetails Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) Details 35 false false R36.htm 00000036 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants-SummaryOfOutstandingWarrantsDetails Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) Details 36 false false R37.htm 00000037 - Disclosure - Stock Compensation (Details Narrative) Sheet http://immunetherapeutics.com/role/StockCompensationDetailsNarrative Stock Compensation (Details Narrative) Details http://immunetherapeutics.com/role/StockCompensation 37 false false R38.htm 00000038 - Disclosure - Income Taxes - Results of Operations (Details Narrative) Sheet http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperationsDetailsNarrative Income Taxes - Results of Operations (Details Narrative) Details http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperations 38 false false R39.htm 00000039 - Disclosure - Licenses and Supply Agreements (Details Narrative) Sheet http://immunetherapeutics.com/role/LicensesAndSupplyAgreementsDetailsNarrative Licenses and Supply Agreements (Details Narrative) Details http://immunetherapeutics.com/role/LicensesAndSupplyAgreements 39 false false R40.htm 00000040 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://immunetherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://immunetherapeutics.com/role/CommitmentsAndContingencies 40 false false R41.htm 00000041 - Disclosure - Subsequent Events (Details Narrative) Sheet http://immunetherapeutics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://immunetherapeutics.com/role/SubsequentEvents 41 false false All Reports Book All Reports imun-20170331.xml imun-20170331.xsd imun-20170331_cal.xml imun-20170331_def.xml imun-20170331_lab.xml imun-20170331_pre.xml true true ZIP 57 0001493152-17-005105-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-005105-xbrl.zip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end